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ABSTRACT  
   
 Anti-retroviral drugs and AIDS prevention programs have helped to 
decrease the rate of new HIV-1 infections in some communities, however, a 
prophylactic vaccine is still needed to control the epidemic world-wide.  
Despite over two decades of research, a vaccine against HIV-1 remains 
elusive, although recent clinical trials have shown promising results.  Recent 
successes have focused on highly conserved, mucosally-targeted antigens 
within HIV-1 such as the membrane proximal external region (MPER) of the 
envelope protein, gp41.  MPER has been shown to play critical roles in the 
viral mucosal transmission, though this peptide is not immunogenic on its 
own.  Gag is a structural protein configuring the enveloped virus particles, 
and has been suggested to constitute a target of the cellular immunity 
potentially controlling the viral load.  It was hypothesized that HIV-1 
enveloped virus-like particles (VLPs) consisting of Gag and a deconstructed 
form of gp41 comprising the MPER, transmembrane, and cytoplasmic 
domains (dgp41) could be expressed in plants.  Plant-optimized HIV-1 genes 
were constructed and expressed in Nicotiana benthamiana by stable 
transformation, or transiently using a tobacco mosaic virus-based expression 
system or a combination of both. Results of biophysical, biochemical and 
electron microscopy characterization demonstrated that plant cells could 
support not only the formation of HIV-1 Gag VLPs, but also the accumulation 
of VLPs that incorporated dgp41.  These particles were purified and utilized in 
mice immunization experiments.  Prime-boost strategies combining systemic 
and mucosal priming with systemic boosting using two different vaccine 
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candidates (VLPs and CTB-MPR – a fusion of MPER and the B-subunit of 
cholera toxin) were administered to BALB/c mice.  Serum antibody responses 
against both the Gag and gp41 antigens could be elicited in mice systemically 
primed with VLPs and these responses could be recalled following systemic 
boosting with VLPs.  In addition, mucosal priming with VLPs allowed for a 
robust boosting response against Gag and gp41 when boosted with either 
candidate.  Functional assays of these antibodies are in progress to test the 
antibodies‟ effectiveness in neutralizing and preventing mucosal transmission 
of HIV-1.  This immunogenicity of plant-based Gag/dgp41 VLPs represents 
an important milestone on the road towards a broadly-efficacious and 
inexpensive subunit vaccine against HIV-1. 
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Chapter 1 
INTRODUCTION 
 
Challenges for Development of an HIV-1 Vaccine 
Since the initial description of Acquired Immune Deficiency Syndrome 
(AIDS) and discovery of its causal agent, Human Immunodeficiency Virus-1 (HIV-
1), in the early 1980s, HIV/AIDS has become a global epidemic with more than 
33 million people currently infected worldwide (Brown et al., 2010).  Antiretroviral 
therapy and AIDS prevention programs have helped to curb the infection rate in 
developed countries, but an estimated 2.6 million new infections in 2009 alone 
prove that the epidemic is not contained worldwide (UNAIDS/WHO, 2009).  
Despite over two decades of research, an effective prophylactic vaccine against 
HIV remains elusive (Johnston and Fauci, 2008).   
Although some countries continue to experience significant rates of new 
HIV-1 infections due to unsanitary reuse of syringe needles or blood 
transfusions, the majority of new infections worldwide are established mucosally, 
in particular the mucosal tissues of the vagina and lower gastrointestinal tract 
(Pope and Haase, 2003).   HIV-1 can breach both pluristratified (multilayered) or 
simple epithelial through a mucosal breach caused by epithelial damage or an 
underlying sexually transmitted disease (illustration of mucosal transmission 
shown in Figure 1).  In addition, HIV-1 can disseminate pluristratified epithelium 
by attaching to dendritic cells.  In simple epithelium with tight junctions, 
transcytosis of HIV-1 can occur through the binding of the membrane proximal 
external region (MPER) of HIV‟s envelope protein subunit gp41 to the galacosyl 
ceramide coreceptor (Alfsen and Bomsel, 2002; Alfsen et al., 2005). Transcytosis  
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Figure 1. Mucosal transmission of HIV.  HIV-1 can gain access through the 
mucosal barrier by several ways: A. mucosal breach (caused, for example, by an 
underlying sexually transmitted disease).  B. In pluristratified epithelium, HIV-1 
can disseminate by attaching to dendritic cells. C. In simple epithelium with tight 
junctions, transcytosis through the cells (mediated by binding of the MPER region 
to galacosyl ceramide) predominates. Transcytosis through M-cells (light blue) is 
also possible. 
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through M-cells of simple epithelium is also possible.  Regardless of the initial 
infection route, the CD4+ cells of the gut-associated lymphoid tissue are the first 
cells to be depleted during the acute phase of HIV infection (Brenchley et al., 
2004; Mehandru et al., 2004).  A vaccine targeted to the mucosal system could 
be one of the most effective methods of stopping the initial infection of the virus.  
The hypervariability of HIV is one of the leading challenges to vaccine 
development.  The high rates of replication, mutation, and recombination all 
contribute to this vast genetic variability of the virus, both globally and within an 
individual (Taylor et al., 2008).  Globally, five different major clades of virus are 
responsible for the majority of infections in different regions around the world, 
with several other clades contributing to the epidemic in regions where the virus 
is most prevalent (Geretti, 2006) (Table 1).  On an individual level, the immune 
system is dealing with rapidly mutating viral antigens outpacing the elicitation of 
effective immune responses against them (Kwong et al., 2002; Leslie et al., 
2004; Kawashima et al., 2009). This creates a “moving target” for potential 
vaccines candidates.  By focusing vaccine targets on highly conserved regions of 
the viral proteome, the vaccine could be more effective at targeting a wider range 
of clades and perhaps offer longer term protection (Johnston and Fauci, 2011).  
In addition to the challenges regarding the hypervariablility of HIV, the lack of 
correlates of immune protection against the virus (Sullivan, 2009; Corey et al., 
2011), the lack of standardized, bona fide animal models for preclinical vaccine 
trials (Girard et al., 2006), and the logistical challenges and costs of clinical trials 
also contribute to the challenges facing researchers striving to develop a vaccine 
candidate (Girard et al., 2006; Corey et al., 2011). 
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Table 1. Global predominance and geographical prevalence of HIV-1 subtypes. 
(Adapted from (Geretti, 2006)) 
 
 
Subtype 
Global 
Predominance 
Main Geographical Prevalence 
A High Eastern Africa, Eastern Europe, Central Asia 
B High Americas, Western Europe, Australia, Japan 
C High 
South and Eastern Africa, India, China, 
Nepal 
D High Eastern Africa, Eastern Europe, Central Asia 
F Low 
South America, Central Africa, Eastern 
Europe 
G Low Central Africa 
H Low Central Africa 
J Low Central Africa 
K Low Central Africa 
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HIV-1 Organization and Virion Structure 
The viral genome contains nine genes that are responsible for the 
production of the virus‟ structural and regulatory proteins, several of which have 
become important targets for protein vaccines against HIV-1 (Figure 2).  Three 
viral genes, gag, pol, and env, give rise to three precursor polyproteins (gag, pol, 
and env) that are responsible for the production of the main structural proteins 
and enzymes of HIV-1.  These polyproteins are then further processed to create 
mature viral proteins.  The structural proteins, Env and Gag, will be further 
discussed below.  In addition to these structural proteins and enzymes, six other 
low molecular mass proteins (Vif, Vpr, Tat, Rev, Vpu, and Nef) are also 
produced.  Tat and Rev play regulatory roles in viral transcription, while Vif, Vpr, 
Vpu, and Nef have been found to be important in viral replication and infectivity 
(Knipe and Howley, 2007). 
On the outermost surface of the virus, HIV-1 expresses the envelope 
(Env) protein consisting of two subunits: gp120 on the surface of the virus and 
the membrane-embedded gp41.  The gp120 subunit is important in initiating viral 
infection by its binding to the primary viral receptor, CD4, present on TH cells, 
dendritic cells, and macrophages (Bour et al., 1995).  This process exposes 
binding sites for the chemokine receptors CCR5 and CXCR4.  Once the virus 
binds to these coreceptors, further conformational changes occur, facilitating the 
fusion of the viral membrane to that of the host and allowing the nucleocapsid to 
enter the cell (Hladik and McElrath, 2008).  In addition to these binding 
mechanisms, the binding of gp41 residues 649-684 encompassing the 
membrane proximal external region (MPER)) to the glycosphingolipid 
galactosylceramide (GalCer) on the apical surface of epithelial cells triggers the  
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Figure 2. Organization of HIV-1 genome.  The HIV-1 genome consists of several 
overlapping open reading frames (ORFs).  The three primary translation products 
for the structural proteins and viral enzymes are synthesized as polyprotein 
precursors, which are then cleaved into mature, particle associated proteins.  
The gag precursor is cleaved into the matrix (MA), capsid (CA), nucleocapsid 
(NC), and p6 proteins.  The pol precursor is cleaved into protease (PR), reverse 
transcriptase (RT), and integrase (IN) proteins.  The env precursor is cleaved into 
gp120 and gp41.  Six other viral proteins (Vif, Vpr, Vpu, Tat, Rev, and Nef) are 
also produced. 
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transcytosis of the virus towards the serosal side of the cell (Alfsen and Bomsel, 
2002). 
The surface subunit of Env, gp120, is highly immunogenic and some of 
the antibodies generated from this protein can mediate viral neutralization during 
natural infection, but unfortunately these neutralizing antibodies are not  
broadly reacting, and are unable to completely eliminate virus from the patient 
due to the rapid mutation of the virus which evade the specific antibodies 
(Montero et al., 2008).  In addition, gp120 is heavily glycosylated, with over 50% 
of the protein surface covered with carbohydrates, which obstruct the binding of 
neutralizing antibodies (Pantophlet and Burton, 2006).  Despite the variability and 
glycosylation of gp120, much research has focused on the CD4 binding site 
(CD4bs) and the adjacent V3 loop of gp120, due to the broadly-neutralizing 
antibody epitopes found within these regions of gp120 (Nandi et al., 2010). 
In contrast to the variability of gp120, the transmembrane glycoprotein 
gp41 contains a highly conserved membrane proximal external region (MPER) 
corresponding to amino acids 649-683 of the protein (Montero et al., 2008).  The 
MPER resides just outside the lipid envelope, above the transmembrane domain 
(TM) of gp41 (Figure 3). 
The MPER of gp41 is important in the viral transcytosis across mucosal 
membranes (Bomsel and David, 2002).  The cell receptor glycosphingolipid 
galactosyl ceramide (GalCer) on the luminal surface of epithelial cells binds to 
the MPER of gp41, mediating the transcytosis of the virus to the serosal side of 
the cell.  This binding can be inhibited by peptides corresponding to the MPER, 
and both mucosal and systemic antibodies against  
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Figure 3. HIV-1 gp41 structure.  The membrane-embedded gp41 subunit of HIV-
1 Env consists of a region that interacts with the gp120 subunit, the membrane 
proximal external region (MPER, a.a. 649-684), the transmembrane domain (a.a. 
685-704), and the cytoplasmic tail (a.a. 705-856).  Two epitopes (ELDKWA and 
NWFDIT) within the MPER recognized by broadly neutralizing antibodies, 2F5 
and 4E10, respectively, are also shown. 
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MPER can block the transcytosis of HIV across the epithelial barrier (Matoba et 
al., 2004; Matoba et al., 2006).   
In addition, the broadly neutralizing human monoclonal antibody 2F5 
(whose core epitope is the ELDWKA sequence within the MPER) and polyclonal 
secretory IgAs (sIgAs) found in the mucosal secretions of highly exposed 
persistently seronegative (HEPS) individuals have been shown to block 
transcytosis (Devito et al., 2000; Broliden et al., 2001; Kaul et al., 2001).   These 
results show potential for mucosal immunity through a vaccine utilizing the MPER 
region of gp41 (Alfsen et al., 2001). 
Since MPER is not immunogenic on its own (Zolla-Pazner et al., 2011), a 
platform with which to introduce the protein as a vaccine candidate is needed for  
successful mucosal immunization.  Past studies from the Mor lab have utilized 
fusion proteins containing the cholera toxin B (CTB) subunit and plague antigens 
F1 and V for mucosal immunizations along with MPER with varying degrees of 
success (Matoba et al., 2004; Matoba et al., 2006; Matoba et al., 2008; Shah, 
2008; Matoba et al., 2011), and these studies will be discussed in more detail in 
Chapter 4. 
Gag, the main structural protein of HIV-1, which plays a key role in virus 
budding, is a potential candidate for a platform with which to introduce the MPER 
peptide in a vaccine candidate.  During viral assembly, the immature p55 Gag 
provides structure for the budding virus, localizing to membrane rafts within the 
plasma membrane where HIV-1 envelope proteins are also localizing 
(Bhattacharya et al., 2006).  The accumulating Gag oligomers bud from the cell 
(Figure 4), taking the host membrane and associated membrane-proteins with it,  
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Figure 4. HIV-1 Gag protein.  A. Schematic representation of the components of 
the p55 Gag polyprotein as comprised in the immature virion, before cleavage by 
viral protease.  B. The budding of HIV Gag from a lipid membrane.  From the left 
to right, Gag proteins line up along the membrane, start to protrude from the cell, 
and then pinch off from the host membrane as an immature virion.  C. Gag 
structures within an immature virus.  The matrix, capsid, nucleocapsid and p6/p7 
are in their immature conformation.  D. Gag protein after cleavage by viral 
protease, with the matrix protein forming the outer structure of the virus and the 
capsid protein encapsulating the viral RNA (not pictured) and the nucelocapsid 
and p7/p6 proteins.   
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and eventually pinch off from the host cell.  After budding, the immature p55 Gag 
protein is then cleaved by viral protease in the maturing virus into the N-terminal 
matrix domain (MA, p17), the capsid domain (CA, p24) encapsulating the RNA 
molecules and retrotranscriptase, the nucleocapsid domain (NC, p7), and the C-
terminal domain, p6, with two spacer peptides (p2 and p1 respectively) 
separating p24/p7 and p7/p6.  The N-terminal p17 domain interacts with the 
membrane and cytoplasmic tail of the gp41 envelope protein and is important for 
viral assembly and release (Freed, 1998).  The C-terminal p6 domain is 
important for the budding of viruses from the host cell (Strack et al., 2003).   
 Gag is a promising vaccine candidate against HIV-1, as the combination 
of the p17 and p24 domains contains the highest density of cytotoxic T-
lymphocyte (CTL) epitopes of any HIV protein (Novitsky et al., 2002; Addo et al., 
2003).  In addition, the immature Gag polyprotein (p55 Gag) is both necessary 
and sufficient for forming enveloped virus-like particles (VLPs) of HIV (Garoff et 
al., 1998).     
VLPs as Vaccine Candidates 
 VLPs consist of structural protein shells of viruses, and do not contain 
genetic material.  The protein shell allows the presentation of itself as particulate 
matter to the immune system.  In addition to providing this immunogenicity of the 
VLP proteins itself, VLPs can be used to display other antigens. 
 VLPs are promising new candidates for viral vaccines, and the success of 
prophylactic VLP-based vaccines such as the human papillomavirus L1 VLP 
vaccines (GlaxoSmithKline‟s Cervarix and Merck‟s Gardasil) provide the 
motivation for continued research on VLP vaccines (Schiller et al., 2008; Stanley, 
2009).  Devoid of nucleic acids, unlike conventional “Jennerian” live-attenuated 
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virus vaccines, VLP-based vaccines are able to initiate protective immune 
responses without the risk of viral infection or other major harmful side effects.  
Gag-based VLPs are capable of inducing strong CTL responses without adjuvant 
(Doan et al., 2005).  The Gag protein of HIV has been shown to produce VLPs in 
various eukaryotic expression systems including mammalian (Rovinski et al., 
1992), insect (Deml et al., 2004), and yeast cell cultures (Sakuragi et al., 2002) 
and shown to be immunogenic (Deml et al., 2005).  Gag is highly conserved 
within clades, relatively conserved across diverse HIV clades, and spans multiple 
CD4+ and CD8+ T-cell epitopes (McAdam et al., 1998; Ferrari et al., 2000).  In 
addition, Gag VLPs can display HIV Env proteins on their surface in their native 
conformation (Hicar et al., 2010), and have been shown to induce both Env- and 
Gag-specific antibodies and CTLs (Rovinski et al., 1992; Montefiori et al., 2001), 
making Gag VLPs attractive candidates for an HIV vaccine platform. 
Expression Host Considerations for HIV-1 Vaccines 
Regardless of the antigen used as a vaccine candidate, the expression 
system with which it is produced is an important factor to consider when 
developing an HIV vaccine.  One of the difficulties in developing an HIV vaccine 
lies in the fact that HIV is most prevalent in sub-Saharan Africa and other 
developing countries, where resources and funding are not readily available for 
distribution of expensive vaccines (International AIDS Vaccine Initiatve, 2006).  
Therefore, in order for the vaccine candidate to truly be effective in reaching at 
risk populations in developing countries, the vaccine must be manufactured, 
stored, and distributed inexpensively.  Production of vaccines in mammalian, 
insect, and yeast cell cultures is expensive and difficult to scale up for production 
on a large scale.  In addition, pathogens and toxins in these cultures present 
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additional hurdles for protein purification and use in human vaccines (Daniell et 
al., 2001; Thanavala et al., 2006).  
 Plants, on the other hand, offer simple and inexpensive means of 
recombinant protein production which can be readily scaled up according to 
production needs in greenhouse or field conditions (Streatfield and Howard, 
2003a, b), while still providing the cellular machinery and eukaryote-common 
post-translational modifications necessary for producing VLPs utilizing the Gag 
and Env proteins.  Plants have been shown to be effective in expressing VLPs of 
Hepatitis B (Kapusta et al., 1999; Kapusta et al., 2001; Huang et al., 2005; 
Thanavala et al., 2005; Huang et al., 2006; Huang et al., 2009), Norwalk virus 
(Tacket et al., 2000; Zhang et al., 2006; Santi et al., 2008), influenza (D'Aoust et 
al., 2008), and even HIV (Meyers et al., 2008; Scotti et al., 2009), and several of 
these VLP-based vaccine candidates have been successful in clinical trials 
(Tacket et al., 2000; Mason et al., 2002). 
Aims of Research and Review of Dissertation 
 Despite the many biological and economical challenges related to the 
development of an HIV-1 vaccine, by addressing these challenges in the context 
of a new vaccine candidate that utilizes a mucosally targeted subunit vaccine 
component focused on highly conserved regions of HIV-1 and expressed in 
highly scalable, inexpensively grown Nicotiana benthamiana, I hoped to create a 
novel immunogen for use as an effective HIV-1 vaccine constituent.  In this 
project, a vaccine candidate based on a Clade C Gag VLP with deconstructed 
gp41 (dgp41, consisting of the MPER, transmembrane domain, and cytoplasmic 
tail region) proteins embedded in its membrane envelope (Figure 5) was  
 
  14 
 
 
Figure 5. Comparison of structures within mature, infectious native HIV-1 virus 
(left) and VLP consisting of p55 Gag and dgp41 (right).   
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expressed in plants and tested for immunogenicity in mice.  The goal of the 
project was to first express p55 Gag in Nicotiana benthamiana in both transient 
and transgenic expression systems.  Then dgp41 was transiently expressed first 
in wild type plants and then co-expressed with Gag in Gag transgenic plants.  
The expression of these proteins is discussed in Chapter 2.  In Chapter 3, these 
expressed proteins were characterized to determine whether they were 
developing into enveloped VLPs.  Once it was established that Gag and dgp41 
were co-localizing into VLPs, the VLPs were purified from plant extract and 
utilized in two separate immunization trials.  The first trial tested the 
immunogenicity of the VLPs in comparison to the fusion peptide CTB-MPR when 
injected into mice intraperitonially (i.p.).  This immunization trial and the results of  
antibody production against p24 and MPER and functional assays are discussed 
in Chapter 4.  A second trial in mice was conducted to test the mucosal response 
of a heterologous prime-boost strategy utilizing both plant-produced VLPs and 
CTB-MPR with intranasal (i.n.) priming and i.p. boosting.  This trial and the 
results of antibody production against p24 and MPER, functional assays, and 
cytotoxic T-cell lymphocyte responses against Gag are discussed in Chapter 5. 
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Chapter 2 
PLANT OPTIMIZATION AND EXPRESSION OF GAG AND DGP41 IN 
NICOTIANA BENTHAMIANA 
ABSTRACT 
 The HIV-1 proteins Gag and gp41 have had limited expression in plants 
in both transient and transgenic expression systems due to a number of factors.  
Through plant codon-optimization and the use of both transgenic expression and 
the MagnICON transient expression system, the expression of both HIV-1 Gag 
and deconstructed gp41 (dgp41) proteins were tested for expression in Nicotiana 
benthamiana.  It was determined that HIV-1 Gag could be expressed by both a 
transient and transgenic expression system, and it was also determined that 
dgp41 proteins could be expressed by a transient expression system.  In 
addition, it was demonstrated that Gag and a deconstructed gp41 (dgp41) can be 
co-expressed in N. benthamiana.   
 
INTRODUCTION 
 HIV-1 Gag, gp41, and their derivatives have been expressed in plants in 
only a handful of studies, and the results of these studies have been mixed.  
Although recombinant Gag has been expressed in other cell culture systems for 
more than 20 years (Gheysen et al., 1989; Shioda and Shibuta, 1990; Vzorov et 
al., 1991; Wagner et al., 1994b; Wagner et al., 1994a; Sakuragi et al., 2002), 
Gag has only been expressed in plants in two studies (Table 2), by Edward 
Rybicki‟s group at the University of Cape Town (Meyers et al., 2008), and 
Teodoro Cardi‟s group at Italy‟s National Research Council Institute of Plant  
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Genetics (Scotti et al., 2009).  Both groups had difficulty in expressing full-length 
p55 Gag in the cytoplasm of N. benthamiana and N. tabacum in either transient 
or transgenic systems.  Both groups had better success with expression of p55 
Gag in chloroplasts, but neither group confirmed the production of enveloped 
VLPs in their study.  Scotti and colleagues (2009) were able to produce 
transmission electron microscopy (TEM) images of their VLPs, but did not 
confirm that these were enveloped (Scotti et al., 2009).  No immunogenic studies 
were performed with either of the p55 Gag products, though Meyers et al. did 
conduct successful mice immunization trials with a protein containing both the 
matrix (p17) and capsid (p24) portions of Gag (Meyers et al., 2008). 
 Several groups have attempted expression of parts of the HIV envelope 
proteins in plants with varying degrees of success (Table 3).  The main 
candidates for plant-expression have been some of the main targets of vaccine 
and microbiocide production: the V3 loop of gp120  (Sugiyama et al., 1995; 
Joelson et al., 1997; Yusibov et al., 1997; Kim et al., 2004), the b12 epitope of 
gp120 (Sexton et al., 2009), the membrane proximal region of gp41 (Marusic et 
al., 2001; Matoba et al., 2004; Matoba et al., 2006), and the cytoplasmic tail of 
gp41 (McLain et al., 1995) (Table 3).  All of these proteins or peptides were 
expressed on a virus platform or as fusion partners with other proteins/peptides, 
but the expression levels of the proteins were fairly low.   
 There are several important factors that affect the success of high-level 
expression of recombinant proteins in plants.  The host in which to express the 
protein of interest can be determined by the end goal of the vaccine, but a wide 
variety of hosts ranging from edible fruits and tubers such as tomatoes and 
potatoes to edible leafy crops such as alfalfa, spinach, and lettuce to non-food  
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crop species such as tobacco and Arabidopsis thaliana have been utilized in the 
past for antigen production (Rybicki, 2010).  In addition to whole plant expression 
systems, plant cell cultures such Nicotiana tabacum –derived cell suspension 
cultures (Fischer et al., 1999a; Fischer et al., 1999b), carrot-cell suspension 
cultures (Shaaltiel et al., 2007; Aviezer et al., 2009), and hairy root cell cultures 
(Skarjinskaia et al., 2008; Woods et al., 2008) have been used in the past, with 
one therapeutic protein from plant cell cultures currently in human trials (Rybicki, 
2010).  Although many factors such as antigen delivery and global vaccine 
quantity requirements need to be taken into consideration in choosing a plant 
expression host at the level of providing proof of principle, many researchers 
have opted to express vaccine antigens in high-biomass model systems such as 
N. benthamiana and tabacum for both proof of concept and production of tested 
vaccine candidates (Sharma and Sharma, 2009; Tiwari et al., 2009).   
 In addition to choosing the expression host, there are several methods to 
choose from in which the recombinant proteins can be expressed within the 
plant.  The main choices for expression systems are based on either stable 
transgenic expression or transient expression.  Of the various methods to stably 
transform the plant genome, the one employing the ubiquitous soil bacterium and 
plant pathogen Agrobacterium tumefaciens has been most widely applied to both 
dicotyledonous plants and to monocotyledonous plants (Rybicki, 2009).  
Alternative methods, like the biolistic (“gene gun”) method, can be used to 
transform other species which have proven to be refractory to Agrobacterium-
mediated transformation (Ye et al., 1990).  Stable transformation techniques 
produce transgenic and transplastomic plants that stably express the proteins of 
interest through subsequent generations (Komari et al., 2006; Komori et al., 
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2007).  Once the genes are introduced into nuclear genomes or plastid genomes 
of small leaf samples, cotyledons, hypocotyls, and other explants, these explants 
are then grown on selective growth media to select for transformed cells, which 
grow as a non-differentiated cell mass or callus.  Regeneration of calli into whole 
plants is achieved through the use of several plant hormones.  Since the 
gametes of such plants will contain the transformed gene of interest, the gene of 
interest will be stably inherited in future generations, allowing for protein 
expression in these generations without the need for successive transformations. 
 Stable transgenic expression is beneficial for the stable expression of 
proteins, as the transgenes are stably inherited and allow for seed production 
and high biomass production.  Unfortunately, the time to develop stable 
transgenic plants can be limiting.  The need to screen many different kinds of 
constructs would require a faster production system.  In addition, if the multiple 
genes are needed for co-expression, multiple transgenic expression can be 
performed but with an even larger time constraint. Therefore transient expression 
of foreign proteins can be applied. 
 Viral vectors based on the genomes of various plant virus families have 
been proposed and examined including those based on tobacco mosaic virus 
(TMV) (Sugiyama et al., 1995) and Gemini virus (GV) (Mor et al., 2003).  For a 
recent review about plant based viral vectors see (Canizares et al., 2005). In 
particular, vectors based on TMV have proven to be successful.  In this work, I 
have used a TMV-based transient expression system.  Although expression with 
viral-vectors by themselves has been successful, the delivery of these viral 
vectors with Agrobacterium tumefaciens has increased relative levels of 
expression and ease by which constructs can be transported into plant cells 
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(Rybicki, 2010).  In this method, termed Agrobacterium-mediated transient 
expression, viral vectors are incorporated into bacterial cells, which are then 
infiltrated into plant cells by needless-syringe or vacuum pressure, resulting in 
the bacterial suspension infiltrating intercellular spaces of infiltrated cells.  The 
combination of agroinfiltration and viral vectors was revolutionized with the 
„Magnifection‟ system of ICON Genetics in 2005 (Gleba et al., 2005).  
Magnification incorporates a “deconstructed” TMV-based vector, and allows 
researchers to choose between several subcellular targeting modules in order to 
target their protein of interest to different parts of the plant cell without having to 
redesign their own construct.  In contrast to stable transgenic expression 
systems, transient expression systems are beneficial for the rapid production of 
antigens in plants, but they are limited in that the expression is contingent on 
continual infiltration of vectors/agrobacterium for generation of recombinant 
proteins.   
 In addition to choosing an expression host and expression system, 
optimizing the gene for expression in plants has also been shown to play a role in 
how well foreign proteins express in plants (Rybicki, 2010).  Codon optimization, 
or replacing infrequently used codons in the gene of interest with codons that are 
more frequently used in the host plant, can increase the expression of the protein 
of interest (Geyer et al., 2007; Geyer et al., 2010).  Codon usage bias is species 
dependent, and these species-specific differences in codon usage have been 
shown to regulate the levels of gene expression, with the primary factors 
affecting expression often cited to be mRNA processing and accumulation 
(Geyer et al., 2007). Moreover, the tRNA levels that serve these codons is not 
uniform and can be rate limiting affecting overall accumulation levels of certain 
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proteins. Therefore, by changing the codons of transgenes to conform wiith that 
of highly expressed proteins in a specific host, the expression of that transgene 
can be increased.  In addition, expression of foreign proteins in plants can be 
increased by removing mRNA destabilizing sequences and potential methylation 
sites in the gene of interest through silent mutations (Perlak et al., 1991; Mason 
et al., 1998).  Although various optimization processes can be successful, it 
should be noted that the process is empirical and can be different for each 
protein of interest, host plant, and expression system (Rybicki, 2010).  
 The expression of Env and Gag in plants was previously attempted in 
several systems (see Tables 2 and 3), but thus far the plant expression of these 
proteins has proved to be difficult.  In this study, plant codon optimization was 
utilized for both proteins.  Transient TMV-based expression (MagnICON) for both 
proteins was utilized, and transgenic expression was also utilized for Gag.  I 
hypothesized that increased accumulation levels of both recombinant proteins 
could be achieved by applying three strategic innovations. First I applied a newly 
developed algorithm to redesign full length Gag and deconstructed variant of 
gp41.  Second I employed one of the most robust expression systems available, 
MagnICON. Third, I combined stable and transient transformation approaches to 
achieve co-expression of the two transgenens. Here I report on experiments 
aimed at testing my hypotheses and demonstrate success of my approach. 
 
MATERIALS AND METHODS 
Plant Optimization and de novo Construction of the gag and dgp41 Genes.   
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The gag gene (from subtype C R5 HIV-1 isolate, 1084i, GenBank 
accession no. AY805330) containing the coding sequences for the entire p55 
Gag protein (Figure 6) was optimized for expression in N. benthamiana using  
methods described in (Geyer et al., 2010).  Codon usage bias in genes encoding 
highly expressed proteins of dicotyledonous plants was assessed according to 
Sharp and Li (1987).  The reference set included cDNAs encoding the small 
subunit 1B of RuBisCO, chlorophyll A ⁄ B binding protein 2, ribosomal protein L1 
and L2, 40S ribosomal protein S2, S3 and S4 (accession nos. NM_123204, 
NM_102733, NM_202757, NM_201956 NM_115247, NM_115247 and 
NM_125228, respectively) of the model plant Arabidopsis thaliana.  The relative 
synonymous codon usage (RSCU = observed frequency ⁄ unbiased frequency), 
the relative  adaptiveness of a codon (w, RSCU normalized to the most abundant 
synonymous codon for an amino acid) and the codon adaptation index (CAI, 
geometric mean of w values over the entire length of the gene) values were 
calculated according to Sharp and Li (1987). Unfavorable (or infrequently used) 
codons were defined here as codons with w < 0.5. This codon bias analysis 
corresponds very well with a recently published analysis (Mukhopadhyay et al., 
2008). Putative RNA-destabilizing sequences were analyzed through a genome-
wide in silico study by Narsai et al. (2007), but only few such sequences were 
positively identified in planta, including the AU-rich elements, AUUUA, AUAGAU 
and UUUUUU.  Briefly, in silico evaluation of the native gag gene was performed 
by codon bias analysis in order to determine the presumed expression levels of 
the gene in plants.  Cryptic sequences such as putative RNA-destabilizing 
sequences, spurious polyadenalation signals, and untoward splicing signals were  
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Figure 6. DNA constructs of gag and dgp41.  A. Gag (top) and dgp41 (bottom) 
constructs, showing domain regions of the corresponding protein, as well as 
codon number of native HIV-1 gene.  B. T-DNA construct of gag in pGPTV-Kan.  
LB - left T-DNA border, Ag7 - Agrobacterium gene 7 poly-A signal, nptIII – 
kanamycin resistance gene, nos - nos terminator, 35S – cauliflower mosaic virus 
35S promoter, TEV - tobacco etch virus 5‟ untranslated region, VSP - 
polyadenylation signal of soybean vegetative storage protein gene, RB - right T-
DNA border.  C. T-DNA constructs of gag (top) and dgp41 (bottom) in the 5‟ 
module of the MagnICON system.  AttB - recombination site, int - intron, NTR - 
non-translated region.  Scale for A. and B. at the bottom of the figure. 
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identified according to (Loke et al., 2005).  The optimized gag gene was 
constructed de novo using the assembly PCR method (Figure 7A) using 
complimentary overlapping oligonucleotides (Stemmer et al., 1995).  A total of 29 
forward and 29 reverse overlapping primers (Table 4, 26-62 bp in length, keeping  
 melting temperatures at 60+/-2°C, ordered from Integrated DNA Technologies) 
were assembled via assembly PCR using the Expand High Fidelity PCR kit 
 (Roche).  The primers at the 5‟ and 3‟ end of the gene (GagF1 and GagR1, 
Table 5) were then used to amplify the entire gene.  The deconstructed gp41 
gene comprises a chimera consisting of the gp41 MPER derived from the B-
clade MN isolate (GenBank accession number AF075722) and the 
transmembrane domain and cytoplasmic tail region of the C clade 1084i isolate 
(GenBank accession number AY805330).  The gene was plant optimized as 
above and ordered from Integrated DNA Technologies. 
 The constructed genes were cloned into the PCR-cloning vector, pTOPO-
TA (Invitrogen) to create pTM 445 and pTM 601 for gag and dgp41, respectively.  
The restriction sites NcoI and SacI were added to the 5‟ and 3‟ ends of the genes 
(Figure 6), respectively, for aid in further cloning and the DNA sequences were 
verified. 
Gag Stable Expression 
 The gag construct from pTM 445 was cloned as per standard procedures 
according to Current Protocols in Molecular Biology (Wiley) into the binary vector, 
pGPTV-Kan (pTM036) (Mor et al., 2001), for stable expression, as previously 
described (Richter et al., 2000) to create pTM 535.   
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Figure 7. De-novo construction of Gag gene.  A. 1. A total of 58 forward and 
reverse overlapping primers (26-62 bp in length) were designed so each half of 
any forward oligonucleotides would be complementary to two adjacent reverse 
oligonucleotides and vice versa.  2. During the first round of PCR, low levels of 
correctly assembled oligonucleotides form a template for a second round of PCR.  
3.  Durin that second round, the entire gene was amplified. B.  DNA gel showing 
both rounds of PCR.  The amplified band (1.6 kb) was purified and cloned into a 
TOPO cloning vector.  
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Table 4. Forward (top) and reverse (bottom) overlapping oligonucleotides used in 
de novo synthesis of gag. 
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Table 5. Oligonucleotides used as primers in this study. 
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 Stable transgenic N. benthamiana expressing Gag were established by 
transforming A. tumefaciens LBA4404 with pTM 535 (pGPTV-Kan vector 
harboring the plant-optimized gag gene, for construct, see Figure 7).  Sterile leaf  
explants (>300) were transformed with these cultures using the Agrobacterium- 
mediated method, as previously described (Figure 8) (Geyer et al., 2007).  
Agrobacterium cultures, grown to logarithmic phase, were harvested by 
centrifugation and resuspended in Agrobacterium-induction media (AIM, 2.15  
g/L Murashige and Skoog (MS) salts, 0.5 mg/L pyridozine, 0.5 mg/L Nicotinic 
acid, 2 mg/L thiamine HCl, 100 mg/L Myoinositol, 0.9 g/L glucose, 1.95 g/L N-
morpholino enthanesulfonic acid (MES), pH 5.2) to an optical density at 600 nm 
of 0.4.  Sterile leaf explants excised from axenic 4 wk old tissue-culture grown N. 
benthamiana were co-cultivated with these cultures using the Agrobacterium-
mediated method, as previously described.     
 Explants were transferred to non-selective plant-growth solid media (4.3 
g/L MS salts, 30 g/L sucrose, 7.5 g/L agar) and allowed to recover for two days 
before being transferred to selective plant-growth solid media (same as above, 
but containing 300 mg/L kanamycin).  Transformed cells were allowed to form 
calli, and surviving calli were transferred to selective plant-growth solid media 
containing 0.1 mg/L 1-naphthaleneacetic acid (NAA) and 1 mg/L 6-
benzylaminopurine (BA) that allowed shoot formation.  Shoots were excised from 
calli and transferred to selective plant-growth solid media containing 0.1 mg/L 
NAA to allow for root formation.  Gag expression in regenerated plants was  
confirmed using immunoblots, and regenerated Gag-expressing plants were 
transferred to soil for seed generation. 
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Figure 8. Development of stable transgenic Gag-expressing plants.  Binary 
vectors (pGPTV-Kan) containing the gag gene were introduced into A. 
tumefaciens, which was then incubated with sterile leaf explants.  Transformed 
cells from the explants were allowed to develop into an undifferentiated cell mass 
(callus) on selective media containing kanamycin.  Callus cells were transferred 
to selective media containing hormones specific for shoot formation.  Shoots 
were transferred to rooting media to allow root formation.  Regenerated whole 
plants were tested for Gag protein and transferred to soil.    
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Transient Gag and Dgp41 Expression   
 A deconstructed TMV Vector system (MagnICON, ICON Genetics, Bayer 
CropScience) was used for transient expression of gag and dgp41 in N. 
benthamiana (Marillonnet et al., 2005).  To this end, the NcoI-SacI restriction  
fragrments from pTM 445 and pTM 601 were cloned into the 3‟ module of the 
ICON system (pTM 202) to yield, respectively, pTM488 and pTM602, which were 
introduced into competenet A. tumefaciens LBA4404 (Figure 9).  For transient 
expression (illustrated in Figure 9), A. tumefaciens LBA4404 cell lines harboring 
the modules of the viral vector and either pTM 488 or pTM 602 were grown to 
logarithmic phase, resuspended in infiltration buffer (10 mM MES, 10 mM 
MgSO4, pH 5.5) at a final optical density at 600 nm of 0.01, and inoculated into 6- 
week old N. benthamiana plants using a vacuum infiltration method.  Plants were 
inverted into a vacuum container containing 2 L of A. tumefaciens and a vacuum 
of 600 mm Hg was applied to the container for 2 min.  The vacuum was quickly 
released, allowing the A. tumefaciens to infiltrate the leaf cells.  Infiltrated plants 
were kept in a controlled environmental growth chamber at 25°C until harvest, 
and expression of Gag and dgp41 proteins were confirmed with SDS-PAGE and 
immunoblotting of the leaf extract.   
Immunoblotting   
For immunoblotting, leaf extract was homogenized with plant extraction 
buffer in a ratio of 1 mg leaf tissue: 3 μl extraction buffer (25 mM 
Na2HPO4/NaH2PO4, 100 mM NaCl, 1 mM ethylenediaminetetraacetic acid 
(EDTA), pH 7.8) and a ceramic bead in a Fast Prep-24 (MB Biomedicals) 
machine for 40 s.  Extract was clarified at 12,000 g for 10 min and the 
supernatant was collected.  Extract (200 µl) was added to 5x SDS  loading buffer  
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Figure 9. Transient expression of gag using the MagnICON system.  A. 
Representation of T-DNA modules used in ICON expression.  Top: 5‟ module. 
Middle: 3‟ modlue. Bottom: Integrase module. LB - left T-DNA border, Act2 - 
Arabidopsis Actin 2 promoter, RdRp - RNA-dependent RNA polymerase, MP - 
movement protein, ats - barley alpha-amylase apoplastic targeting sequence, int 
- intron, AttP and AttB - srecombination sites, nos - nos terminator, NTR - non-
translated region, RB - right T-DNA border.  B. Flowchart of transient expression.  
Vectors are introduced into Agrobacterium and cultured to logarithmic phase.  
Plants are then suspended in Agrobacterium culture and subjected to vaccum 
infiltration.  Once Agrobacterium is inoculated into cells, the vectors of the ICON 
system work together to recombine in the nucleus.  The recombineed modules 
are spliced and exported to the cytoplasm where the assembled vector can 
replicate and be translated into the dgp41 protein.  
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(40 µl, 30% glycerol, 35 mM SDS, 60 mM DTT, 18 mM bromophenol blue, 350 
mM Tris-HCl, pH 8.0) and incubated for five min at 100°C to denature the 
proteins.  12% polyacrylamide gels were prepared and each sample (20 µl) was 
loaded into its respective well.  Gels were run at 40 mV until proteins were 
separated.  Proteins were then transferred to nitrocellulose membrane and 
blocked with PBST containing 5% dry milk (PBST-M) for 1 h at 25°C.  
Membranes were then incubated for 1 h in primary antibody solution containing 
blocking buffer and either a 1:5,000 dilution of a polyclonal anti-p24 rabbit serum 
(for detection of Gag protein) or a 1:10,000 dilution of a monoclonal 2F5 
antibody, a kind gift from Morgane Bomsel (for detection of dgp41).  Membranes 
were triple-washed for 30 min and then incubated with a 1:10,000 dilution of a 
secondary antibody conjugated to HRP (anti-rabbit IgG for p24 and anti-human 
IgG for 2F5) for 1 h at 25°C.  Membranes were then triple washed for 30 min, 
developed with ECL reagent (Santa Cruz), and exposed to film. 
 The quantification of proteins was performed with quantitative 
immunoblotting (Figure 10).  Pure samples of either p24-CTA2 or CTB-MPR 
were used as standards, and 10 µl samples containing 50, 40, 30, 20, or 10 µg of  
p24 (80% mass of p24-CTA2) or the MPER peptide (33% mass of CTB-MPR) 
were loaded onto a SDS-PAGE gel.  Unknown samples were also loaded onto 
the gel in several dilutions (dependent upon sample, ie. crude extract or partially  
enriched fraction).  The gel was run and processed as above.  The resulting 
developed blot was scanned as a color image using an HP4050 (Helwett-
Packard) scanner and the raw image was imported into ImageJ software.  The 
background of the image was removed, and the lanes were separated using the  
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Figure 10. Quantitative immunoblot quantification.  A.  Raw image of immunoblot 
showing lanes corresponding to both known (50-10 ng/well) and unknown (U) 
quantities of p24.  B.  Immunoblot in ImageJ with background removed and lanes 
separated.  C. Pixel area as calculated by ImageJ.  D. Standard curve generated 
from the pixel area results. 
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gel analyzer tool.  The pixel area of each lane was calculated using the software, 
and a standard curve was generated based on these pixel areas.  The unknown  
protein concentration of p24 or MPER in the samples was generated from these 
standard curves. 
Generation of Anti-p24 Antibodies 
 In order to develop anti-p24 antibodies, a fusion construct consisting of 
the plant-optimized p24 gene and the cholera toxin A2 subunit (CTA2) was first 
developed.  The gene for p24 was PCR amplified from the plant-optimized gag 
gene with primers oTM374 and oTM375 (Table 5), which added the FacsI and 
FseI restriction sites to the 5‟ and 3‟ ends of the gene, respectively (Table 5). The 
amplified gene product was cloned into pTM319, a pET-22b(+)  E. coli 
expression vector containing the gene for CTA2, to create pTM 460.  The p24 
gene was cloned in-frame upstream of the CTA2 gene.  The p24-CTA2 fusion 
construct was expressed in E. coli BL21 (DE3) cells and purified as previously 
described (Matoba et al., 2008).  Briefly, E. coli cultures containing pTM 460 
were grown from single colonies overnight at 37°C.  Logarithmic phase cultures 
were induced with 100 μM isopropyl β- D -1-thiogalactopyranoside (IPTG) and 
allowed to grow for 2 h before centrifugation of the cells.  Cell pellets were 
resuspended in PBS (20 ml) and lysed by microfluidization.  Lysed cells were 
pelleted by centrifugation, and the insoluble pellet was solublized in 8M urea 
buffer (50 mM Tris, 500 mM NaCl, 8 M urea, pH 8.0), rocked at 4°C for 60 min, 
centrifuged to remove the remains of the insoluble cell fractions, and dialyzed in 
PBS with a 10 kD-cutoff membrane for 24 h to remove urea.  The soluble 
supernatant was then added to a 3 ml bed volume Talon gravity flow column and 
purified by metal affinity chromatography.  The final column eluate (6 ml) was 
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dialyzed in PBS with a 10 kD-cutoff membrane for 24 h to remove imidizole.  
Protein remained souble throughout the dialysis.  Purity and quantification of the 
pure p24-CTA2 was determined by Coomassie stained gels, immunoblots, and 
by determining the absorbance at 280 nm using (ɛ = 1.22 mM-1 cm-1).   Two New 
Zealand white rabbits were inoculated with 4 subcutaneous injections of 200 µg 
p24-CTA2 emulsified with Freund‟s complete adjuvant (100 µl at 4 sites per 
rabbit, 0.5 µg/µl p24-CTA2 in sterile PBS).  Rabbits were boosted with 4 
subcutaneous injections of 200 µg p24-CTA2 emulsified with Freund‟s 
incomplete adjuvant (100 µl at 4 sites per rabbit, 0.5 µg/µl p24-CTA2 in sterile 
PBS) two weeks after the initial inoculation.  The level of antibody response was 
determined by p24 ELISA (explained in detail in Chapter 4), and the rabbits were   
exsanguinated upon peak response observed (two weeks following boost).  More 
than 120 ml of blood was collected from each rabbit, and the serum (>90 
ml/rabbit) was separated from the red blood cells by centrifugation at 4,000 g for 
10 min.  Serum was allocated into 1 ml fractions and stored at -80°C until use.    
 
RESULTS 
The de novo Construction of Plant-expression Optimized gag and dgp41 Genes. 
 To increase the level of transcription of the two HIV-1 genes under the 
two expression modalities explored here, stable transgenic expression was 
driven by the strong constitutive cauliflower mosaic virus 35S promoter and by 
the vigorous activity of TMV‟s RNA dependent RNA polymerase (RdRp) of the 
MagnICON transient expression system. In addition, to reduce the extent of DNA 
methylation of the gag transgene, associated in plants with transcriptional gene 
silencing, 49 of the 85 potential methylation sites present in the native gene were 
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abolished by silent mutations introduced into the plant-optimized version of the 
gene. 
Beyond transcription rates, the accumulation of recombinant proteins in 
plants can be greatly affected by post-transcriptional, translational and post-
translational events. To this end, I have removed from the plant-expression 
optimized gag gene all 30 spurious splicing signals (Hebsgaard et al., 1996), 
cryptic polyadenylation sites (Loke et al., 2005) and mRNA destabilizing 
sequences with which the native sequence was ridden (Figure 11). Similarly, 14  
such deleterious sequences were removed from the sequence of the plant-
optimized dgp41 sequence (Figure 12). 
Translatability of foreign gene transcripts can be increased by replacing 
unfavorable codons with synonymous codons that are more widely used in plant 
genes of highly expressed proteins. My analyses demonstrated that 
approximately a third of the codons in the native gag and dgp41 genes were 
unfavorable for expression in plants (33% and 32% of the codons, respectively, 
had w<0.5, for definition see the Materials and Methods section above). In the 
plant-expression optimized versions of the gag and dgp41 genes, the majority of 
the unfavorable codons have been eliminated reducing their occurrence, 
respectively, to 7% and 2% (Figures 11 and 12).  In accordance with these 
results, the calculated codon adaptiveness (CAI) increased from 0.5 to 0.8 (gag) 
and from 0.6 to 0.9 (dgp41) similar to the CAI value of the small subunit of 
ribulose-1,5-bisphosphate carboxylase oxygenase (RuBisCO, CAI value = 0.8), a 
nuclear encoded protein that accumulates to very high levels (Figure 13).  
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Figure 11.  Sequence alignment of native and plant-optimized gag genes and 
their expected translation product.  Both genes encode for an identical protein 
(top line), but the nucleotide sequence of the native gag was adapted to allow 
higher levels of expression in designing the plant-optimized gag gene (bottom 
line).  Various molecular features that were targeted in optimizing the gene are 
labeled as shown on the figure.   
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Figure 12.  Sequence alignment of native and plant-optimized dgp41 genes and 
their expected translation product.  Both genes encode for an identical protein 
(top line), but the nucleotide sequence of the native dgp41 was adapted to allow 
higher levels of expression in designing the plant-optimized dgp41 gene (bottom 
line).  Various molecular features that were targeted in optimizing the gene are 
labeled as shown on the figure.   
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Figure 13. Codon usage of plant-optimized gag and dgp41 is comparable to that 
of a highly expressed plant gene.  Plotted values of the relative adaptiveness, w, 
of each codon represent a moving average (geometric mean, window size 51) 
centering on each codon for the coding regions of rbcS1B (encoding the small 
subunit of the enzyme RuBisCO) and both native and plant-optimized gag (A) 
and dgp41 (B).  The codon adaptation index (CAI, relative adaptiveness 
averaged over the length of a sequence) for each gene is shown as a broken 
line. 
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Gag Transient and Stable Expression   
Transient virus-assisted expression of the plant-optimized Gag gene in N. 
benthamiana was confirmed by immunoblotting.  The results (Figure 14) showed 
a prominent band at 55 kD, corresponding to the intact p55 Gag polyprotein, as 
well as two smaller truncated products containing p24 (corresponding to ~48 and 
41 kD).  Similar HIV-1 Gag protein degradation products have been detected in 
HIV-1 Gag produced in mammalian cells (Fouchier et al., 1997; Mullner et al., 
2008).  Expression of gag protein peaked at 10 days post-infiltration (dpi), after 
which point the leaves became yellow and necrotic. Two lines of stably 
transformed N. benthamiana which expressed the Gag protein as determined by 
SDS-PAGE followed by immunoblot analysis were generated.  Immunoblot 
results (Figure 15) again showed a prominent band at 55 kD, and lower 
expression of the degradation products as compared to the transiently expressed 
Gag protein.  It is interesting to note that out of more than 300 explants, only two 
gag-positive plants had been regenerated, however these two plant lines were 
phenotypically indistinguishable from wild type plants, at least under normal 
greenhouse growth conditions.  Quantification of the stably-expressed Gag was 
determined by quantitative immunoblot to be approximately 22 mg/kg fresh 
weight. 
Dgp41 Transient Expression   
 The deconstructed gp41 was first expressed in wild type N. benthamiana 
using an ICON apoplastic targeting module containing the barley alpha-amylase 
signal peptide.  Expression was confirmed using immunoblotting (Figure 16), 
showing a prominent band at 24 kD, the expected size of the dgp41 protein.  As  
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Figure 14. Transient expression of Gag.  WT – Non-infiltrated control plant 
extract.  1, 2, and 3 are three samples of three independently infiltrated plants 
that were harvested 9 days post-infiltration.  Gag protein was detected using 
rabbit α-p24 antiserum. 
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Figure 15. Expression of Gag in transgenic plants.  WT – Wild type plant extract.  
Two lines (#72 and 42) were created.  T0 is the first generation, T1 is the second 
generation for both of those lines.  Immunoblot developed with α-p24 antibodies.  
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Figure 16. Transient expression of dgp41.  NI – Non-infiltrated wild type.  1, 2, 
and 3 are three samples of three independently infiltrated plants that were 
harvested 5 days post-infiltration.   Immunoblot developed with 2F5 antibodies. 
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expected, targeting the recombinant protein to the cytoplasm did not allow its 
accumulation to detectible levels (data not shown).  Interestingly, using 
alternative 5‟-modules equipped with different signal peptides, including those of 
apple pectinase, rice alpha-amylase, and N. plumbagenifolia calreticulin, resulted 
in expression which was below the detection level of my immunoblot assay. 
Once expression was confirmed in wild type plants, stable lines 
expressing the Gag protein were infiltrated with the dgp41 constructs.  Co-
expression of both proteins in these plants was confirmed by immunoblotting  
 (Figure 17).  Interestingly, the co-expression of the two proteins seemed to 
stabilize the proteins and allowed their accumulation to higher levels as 
compared to their expression on their own.  Quantification of gp41 when co-
expressed with stably-expressed Gag was determined by quantitative 
immunoblot to be approximately 9 mg/kg fresh leaf weight. 
 
DISCUSSION 
 Although the expression of HIV-1 Gag and envelope proteins, as well as 
their derivatives, have been expressed extensively in mammalian (Krausslich et 
al., 1993; Wagner et al., 1994b; Hammonds et al., 2007), insect/baculovirus 
(Gheysen et al., 1989; Griffiths et al., 1993; Brand et al., 1995b; Deml et al., 
1997b; Deml et al., 2004; Jaffray et al., 2004; Hammonds et al., 2007; Wang et 
al., 2007; Speth et al., 2008; Tagliamonte et al., 2010), and yeast (Sakuragi et 
al., 2002; Morikawa et al., 2007; Powilleit et al., 2007) cell cultures, data 
concerning their expression of in plants are scant.  Only a few published studies 
described the expression of derivatives of Gag (p24 and/or p17) in plants, but  
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Figure 17. Coexpression of Gag and dgp41.  The coexpression of Gag and 
dgp41 seemed to stabilize the expression of both proteins as compared to the 
expression of either protein by itself, suggesting that the two proteins might be 
interacting with each other, possibly in the context of a VLP. 
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only two have produced full length p55 Gag in plants (Meyers et al., 2008; Scotti 
et al., 2009) and both studies reported little or no success when the protein was 
directed to accumulate in its natural subcellular compartment, the cytoplasm. 
Better accumulation levels were reported when the protein was expressed in 
chloroplasts (i.e. transplastomic plants) or targeted to the organelle following 
transient or stable nuclear transformation (Meyers et al., 2008; Scotti et al., 
2009).  In contrast, my approach as was documented in this chapter, led to 
successful accumulation of the full-length Gag protein in the cytoplasm, when a 
plant-expression optimized version of the gene was either transiently expressed 
using a deconstructed TMV-based system (MagnICON) or integrated stably in 
the plant genome. 
 It is difficult to predict methods by which plant-expression of HIV-1 
proteins can be enhanced, and according to some researchers, this process is 
largely empirical (Rybicki, 2010), and therefore it is suggested that a plethora of 
expression systems, expression hosts, subcellular targeting strategies, and 
codon optimization strategies should be employed for each protein of interest in 
order to determine its optimal method of plant expression.   While this can be 
prohibitively expensive and time consuming for a single lab to investigate, by 
combining the knowledge obtained in all published studies related to plant-based 
expression of the protein of interest, the most favorable expression strategies 
can be deduced.  In this case, two other published studies attempted the 
cytoplasmic expression of HIV-1 p55 Gag in addition to this study.  Meyer et al. 
used a Clade C gag gene as the basis of their expression studies, while Scotti et 
al. utilized a Clade B gag gene as their expression target.  Meyer et al. utilized a 
variety of codon-optimization strategies including native genes and both human- 
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and Nicotiana-optimized genes, while Scotti et al. opted to use only native genes 
(with no codon optimization) for their expression.  In addition, great differences in 
expression systems were also utilized between groups.  For transient expression, 
Meyer et al. utilized a TMV based system (TMV GenewareTM, Large Scale 
Biology) as well as agroinfiltration with binary vectors while Scotti et al. utilized 
only agroinfiltration with binary vectors.  In regard to amino acid sequence of the 
protein, final codon optimization strategy, and transient expression systems, this 
study was more similarly aligned with Meyer et al. in that a Clade C HIV-1 gag 
gene was used as a template, plant-codon optimization was utilized, and a TMV-
based transient expression system was used.  Interestingly, the transient 
cytoplasmic expression of p55 Gag in this study was similar to that of Meyer et 
al. who achieved 2-44 μg/kg p24 using transient expression of plant-optimized 
p55 Gag.  In addition, their transient cytoplasmic expression of native (non-
codon-optimized) p55 Gag yielded less than 0.01 μg/kg p24, results that aligned 
with Scotti et al‟s complete lack of transiently expressed cytoplasmic p55 Gag.  
These results suggest that plant-optimization of the gag gene could positively 
influence the expression of the protein in plant cytoplasm.  Despite this fact, it is 
still difficult to compare plant-codon optimization strategies between this study 
and that of Meyer et al., as their optimization strategy was not published.  In this 
project‟s strategy, employing the removal of mRNA destabilizing sequences, 
poly-A-like signals, potential methylation sites, intron splice recognition 
sequences, and unfavored codons could be responsible for the differences in 
transient expression of p55 Gag in the cytoplasm in comparison to Meyer et al.  
In addition, the use of the ICON system could also have played a role in this 
study‟s higher expression levels.  Regarding nuclear transformation of p55 Gag, 
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Meyer et al. utilized pPAM-derived (Genebank Accession number AY027531) 
binary vectors, while Scotti et al. utilized pBIN plus (ImpactVector) binary vectors.  
It is difficult to compare the three different binary vector systems used in the 
three studies, but neither Meyer et al. or Scotti et al. developed stable transgenic 
lines expressing p55 Gag in the cytosol, suggesting that this study‟s binary vector 
system (pGPTV-kan) is more suitable for this expression, although the combined 
factors of plant-optimization and virus clade could also play a role. 
 The expression of envelope proteins and derivatives within plants has 
been varied (Table 3), but no more extensive than that of Gag expression.  Due 
to the varied nature of the various constructs, it is difficult to compare them to 
each other, but to date, only two other groups have focused on the expression of 
MPER epitopes in plants.  A deconstructed gp41 (dgp41), containing the 
cytoplasmic tail, transmembrane domain, and MPER domain of gp41, using a 
deconstructed TMV-based system (ICON) was successfully expressed in this 
study. 
 In addition to expressing both of these proteins separately, co-expression 
of the two proteins was successful.  In all of more than 30 plants examined (more 
than 10 each of transgenic Gag plants without dgp41, dgp41 expressed in wild 
type plants, and transgenic Gag plants expressing dgp41), the co-expression of 
the two proteins seemed to stabilize the expression of both Gag and dgp41.  This 
phenomenon promisingly suggests the interactions of the two proteins, possibly 
within the context of an enveloped virus-like particle (VLP).  The characterization 
of how these proteins are interacting within the context of the plant cell will be 
discussed in Chapter 3. 
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Chapter 3 
BIOCHEMICAL CHARACTERIZATION OF GAG/DGP41 EXPRESSION 
 
ABSTRACT 
 Displaying the MPER peptide in its native conformation is vital to its 
potential role as a vaccine component.  Enveloped virus-like particles (VLPs) are 
able to display HIV-1 Env proteins within the context of the envelope membrane, 
as has been proven in mammalian, insect, and yeast cells.  Although plants have 
the eukaryotic cellular machinery necessary for the formation of HIV-1 
Gag/dgp41 VLPs, this phenomenon has not been characterized to date.  
Through a series of biochemical, biophysical, and transmission electron 
microscopy characterization, the formation of HIV-1 Gag VLPs in N. benthamiana 
was confirmed, and it was also determined that the VLPs are incorporating 
dgp41. 
 
INTRODUCTION 
 As discussed at some length in Chapter 1, the MPER domain of the HIV-
1 envelope protein gp41 is considered to be a potentially important component in 
a subunit vaccine against the virus. But to be effective as an immunogen, it is 
likely that the MPER would need to mimic its conformation in the native HIV-1 
virus, and consequently, it needs to be presented in the context of a membrane 
(Visciano et al., 2011). Enclosed membrane vesicles with viral membrane 
proteins construe one kind of virus-like particle (VLP) and have been 
demonstrated in the past to be of value as immunogens (e.g. hepatitis B surface 
antigen (Roldao et al., 2010)). However, HIV-1‟s gp41 cannot form VLPs on its 
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own and requires the vesicle-forming function of Gag. Therefore, it was 
hypothesized that enveloped VLPs consisting of Gag that incorporated dgp41 
into the membrane of the VLPs may present the MPER in its natural state.    
 Several components of human cellular machinery are necessary for the 
assembly and budding of HIV-1 VLPs from the cell.  In order for VLPs to form 
and bud from the cell, the Gag protein must be post-translationally modified by 
several enzymes.  An N-terminal myristoyl group must be covalently attached (N-
myristoylation) to the terminal glycine of the matrix portion of the Gag protein 
covalently by N-myristoyl-transferase (NMT) during translation to increase 
membrane affinity of Gag.  Most eukaryotes have two NMT genes (Podell and 
Gribskov, 2004) which have been sufficient for VLP production in mammalian, 
insect, and yeast cell cultures. 
 In addition to the presence of an N-terminal myristoyl group, membrane 
targeting of Gag also requires the presence of phosphatidylinositol 4,5-
bisphosphate (PI(4,5)P2), a phospholipid located at the plasma membrane in 
mammals (Campbell et al., 2001; Saad et al., 2007; Patil et al., 2010).  The 2‟ 
fatty acid occupies hydrophobic cavity of the Gag matrix, and negatively charged 
phosphate groups on the inositol ring interact with basic residues of the matrix.  
This binding changes conformation of the matrix so that the N-terminal myristoyl 
group becomes exposed and therefore increases the affinity of Gag to the 
plasma membrane (Saad et al., 2007).   
 The N-myristoylation of the matrix protein and PI(4,5)P2  are both 
important for targeting of Gag to the membrane, but in order for a VLP to bud out 
of the cell, additional cellular components are required.  For VLP budding within 
mammalian cells, the endosomal sorting complex required for transport (ESCRT) 
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plays an important role (Jager et al., 2007; Pincetic and Leis, 2009).  Two 
epitopes, PTAP and YPLTSL, on the C-terminus of Gag‟s p6 domain are 
involved in the ESCRT pathway (Strack et al., 2003).  PTAP (which is dominant) 
binds the cellular ESCRT protein, Tsg101 (Stuchell et al., 2004), and YPLTSL 
binds ALIX/AIP1 (Strack et al., 2003).  In addition, the monoubiquitination of the 
p6 L domain is required.  It is not understood why this is important, although it is 
speculated that this monoubiquitination could possibly increase the binding of p6 
to Tsg101 (Strack et al., 2003).   
 HIV-1 VLPs have been shown to assemble in mammalian (Krausslich et 
al., 1993; Wagner et al., 1994b; Hammonds et al., 2007), insect (Yamshchikov et 
al., 1995; Deml et al., 1997b; Deml et al., 2004; Jaffray et al., 2004; Wang et al., 
2007; Tagliamonte et al., 2010, 2011), and yeast cells (Sakuragi et al., 2002; 
Morikawa et al., 2007), but despite several attempts, expression of HIV-1 VLPs in 
plants has never been successfully demonstrated in the cellular compartment 
equivalent to that of its natural assembly place – the cytoplasm.  Two studies 
(Meyers et al., 2008; Scotti et al., 2009) were successful in expressing full-length 
p55 Gag within the chloroplasts of cells, but both had difficulty in expressing Gag 
within the plant cytoplasm.  Chloroplast expression might present problems for 
creating an enveloped VLP due to the double-membrane nature of chloroplasts 
and the lack of cellular machinery within the plastids for budding of the VLPs 
outside of the plastid.  Although two studies were able to express p55 Gag in 
plants, only Scotti et al. were able to visualize that the p55 Gag formed VLPs, 
and neither of the studies looked into the characterization of the VLPs.  In this 
chapter, the characterization of plant-produced Gag/dgp41 VLPs will be 
examined. 
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MATERIALS AND METHODS 
Sucrose Density Sedimentation 
Initial characterization of VLPs was performed using sucrose density 
gradient sedimentation as well as 30% sucrose cushions.  For sucrose density 
gradients, 14×89 mm Ultra Clear tubes (Beckman-Coulter) were layered from the 
bottom with 1.5 ml each of 70%, 60%, 50%, 40%, 30%, and 20% (w/v) sucrose in 
phosphate-buffered saline (PBS), pH 7.4.  Clarified, water-soluble leaf extract (3 
ml) was layered on the top of the sucrose gradient and the tube was spun at 
35,000 rpm in a SW41Ti rotor (Beckman-Coulter) for 5 h at 4°C.  For 30% 
sucrose cushions, 70% sucrose (1 ml) was layered on the bottom of 30% 
sucrose (2 ml), and an upper layer of 20% sucrose (2 ml).  Clarified, water-
soluble leaf extract (7 ml) was layered on top of the sucrose and gradient was 
processed as the sucrose gradients.  Fractions (1 ml) were collected from the top 
of the gradients and cushions by pipetting from the gradients and cushions, 
analyzed as described below, and used in further experimentation.   
Optiprep Density Sedimentation 
Further characterization and purification of VLPs was performed using 
Optiprep (60% iodixanol in water, Sigma Aldrich) density gradient sedimentation 
as well as 30% Optiprep cushions.  For Optiprep density gradients, 14×89 mm 
Ultra Clear tubes (Beckman-Coulter) were layered from the bottom with 1.5 mls 
each of 60%, 50%, 40%, 30%, 20%, and 10% iodixanol.  Clarified, water-soluble 
leaf extract (3 ml) was layered on the top of the Optiprep gradient and the tube 
was spun at 35,000 rpm in a SW41Ti rotor (Beckman-Coulter) for 5 h at 4°C.  For 
30% Optiprep cushions, 50% iodixanol (1 ml) was layered on the bottom of 30% 
iodixanol (1 ml), and an upper layer of 20% iodixanol (1 ml).  Clarified, water 
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soluble leaf extract (9 ml) was layered on top of the iodixanol and the tube was 
spun at 35,000 rpm in a SW41Ti rotor (Beckman-Coulter) for 5 h.  Fractions (1 
ml) were collected from the top of the gradients and cushions by pipetting from 
the gradients and cushions, analyzed as described below, and used in further 
experimentation.   
Trypsin Digestion Assay 
 Enriched fractions containing VLPs were digested with trypsin in the 
presence or absence of 1% Triton X-100 as per Sakuragi et al (2002).  VLP-
enriched fractions, containing 200 µg/ml p24 obtained from Optiprep gradient 
centrifugation, were aliquoted (1 ml) to each of four 1.5 ml centrifuge tubes. 
Protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride (PMSF)) were added 
to tubes 1 and 2, while tube 3 and 4 contained no protease inhibitors.  Tube 1 
remained a negative control, while 1% Triton X-100 was added to tubes 2 and 4, 
and trypsin (final concentration 1 µg/ml) was added to tubes 3 and 4.  Extract 
was incubated at 26°C for 30 min, and was analyzed for Gag protein by 
immunoblotting following digestion. 
Transmission Electron Microscopy  
For visualization of whole VLPs, clarified extract from transiently 
expressing Gag plants and Day 6 post-infiltration Gag/dgp41-expressing plants 
was incubated for 2 min on 200 mesh formvar coated grids and stained by 
incubating grids containing sample with 2% (w/v) uranyl acetate for 2 min.  For 
visualization of VLPs in situ, leaf tissue (cut into 1 mm2 sections) from Day 8 post-
infiltration Gag-expressing plants was chemically fixed in primary fixation buffer 
(2% (v/v) gluteraldehyde, 0.1 M Na2HPO4/NaH2PO4, pH 6.8) for 2 h at 25°C.  
Following primary fixation, tissue was washed with phosphate buffer (pH 6.8) and 
  56 
incubated in secondary fixation buffer (2% (w/v) osmium tetroxide0.1 M 
Na2HPO4/NaH2PO4, pH 6.8) for 2 hr at 25°C.  Following fixation, samples were 
washed three times with phosphate buffer (pH 6.8) to remove osmium tetroxide, 
and then incubated with 0.5% (w/v)urynl acetate for 2 hr at 25°C to stain 
samples.  Stained samples were completely dehydrated with ethanol (10 min 
incubations with five increasing concentrations of ethanol for a total of 60 min 
dehydration time) and then infiltrated with a 1:3 ratio of Spurr‟s resin: acetone.  
After a 4 h incubation in 1:3 Spurr‟s resin: acetone, samples were moved to a 1:1 
Spurr‟s resin: acetone mixture for another 4 h incubation at 25°C.  Additional 4 h 
incubations with 3:1 and 100% Spurr‟s resin were performed to completely 
embed the samples in resin.  Fresh resin was then added to samples and the 
mixture was placed into molds and heated in a 60°C oven for 24 h.  Leaf tissue 
from transgenic Gag plants as well as Gag plants expressing dgp41 were also 
fixed and immobilized in the same manner.  Sections (70 nm) from these 
samples were cut on diamond knives, positioned on formvar coated grids and 
stained with 2% uranyl acetate and 2% lead acetate as above.  Specimen grids 
were viewed on a Philips CM12S transmission electron microscope. 
Protoplast Experiments   
Leaves (10 g) of transgenic Gag-expressing plants were surfaced 
sterilized with 70% ethanol, rinsed in water, cut into ~1 cm2 sections, and 
immersed in protoplast isolation buffer (20 ml, 0.625 M sucrose, 25 mM MES, pH 
5.7) containing cellulase (2.5 mg/ml) and pectinase (4 mg/ml) for 1 h at 25°C.  
The protoplast isolation buffer was then carefully siphoned off and replaced with 
fresh isolation buffer and gently shaken (50 RPM) for 5 min.  The solution 
containing released protoplasts was then centrifuged at 200 g for 5 min to pellet 
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any remaining cell debris and the supernatant containing live protoplasts was 
carefully transferred to a sterile petri dish and incubated for 6 h at 25°C with 
gentle shaking (50 RPM), with supernatant samples taken at the indicated time 
points for further analyses. 
 
RESULTS 
Co-sedimentation of Gag and dgp41. 
Virion and VLPs have characteristic size and densities and can be 
separated from other cellular component by rate-zona centrifugation (commonly 
referred to as gradient centrifugation). I subjected clarified homogenates of leaf 
material to both sucrose gradient centrifugation (20-70%, step gradient) and 
optiprep® (iodixanol) gradient centrifugation (20-60%, steps).  Results of sucrose 
(Figure 18) and optiprep (Figure 19) gradient sedimentation experiments 
demonstrated that a large portion of both the Gag and dgp41 proteins migrated 
well into the gradients and could be recovered in the 30-50% sucrose fractions or 
the corresponding the 20-30% optiprep fractions. Similar results were previously 
reported for HIV-1 VLPs from other sources such as insect cells (Buonaguro et 
al., 2001) and yeast (Sakuragi et al., 2002).  For later pufication purposes I 
substituted density gradient fractionation with simpler 30% sucrose or optiprep 
cushions. 
Plant-produced HIV-1 VLPs are Enveloped 
 The previous results suggested that Gag/dgp41 may co-localize to the 
same particles, which would further suggest that the particles may be enveloped. 
This hypothesis was tested by subjecting to proteolysis by trypsin the Gag/dgp41  
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Figure 18. Sucrose Gradient Co-localization of Gag and dgp41.  Lane 1: Wild 
type control.  Lane 2: Whole extract Lane 3: Sample fraction.  Lane 4: 20% 
Sucrose fraction. Lane 5: 30% Sucrose fraction.  Lane 6: 70% Sucrose fraction.  
Upper panel is Coomassie stained gel.  Middle panel is immunoblot showing Gag 
protein (anti-p24 antibodies).  Bottom panel is immunoblot showing dgp41 protein 
(2F5 antibody).   
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Figure 19. Optiprep Co-localization of Gag and dgp41.  Lane 1: Wild type 
control.  Lane 2: Whole extract Lane 3: Sample fraction.  Lane 4: 10% iodixanol 
fraction. Lane 5: 20% iodixanol fraction.  Lane 6: 30% iodixanol fraction.  Lane 7: 
40% iodixanol fraction. Lane 8: 50% iodixanol fraction. Lane 9: 60% iodixanol 
fraction. Upper panel is Coomassie stained gel.  Middle panel is immunoblot 
showing Gag protein (anti-p24 antibodies).  Bottom panel is immunoblot showing 
dgp41 protein (2F5 antibody). 
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optiprep gradient centrifugation-enriched preparations.  Results (Figure 20) 
demonstrate that plant-derived Gag protein within VLPs is protected from trypsin 
digestion.  When VLPs were treated with a detergent that solubilizes and 
removes the membrane, thereby exposing the membrane-enclosed Gag protein, 
the latter now became susceptible to proteolysis. Thus my results essentially 
mimic the case of HIV-1 VLPs produced in other expression systems (Spearman 
and Ratner, 1996; Sakuragi et al., 2002) and are supportive of the suggestion 
that plant-produced Gag/dgp41 VLPs are organized in a fashion not unlike their 
animal-cell derived counterparts. 
HIV-1 VLPs Can Be Directly Observed in situ and in Preparation by TEM 
 Transmission electron microscopy was performed on both the leaf extract 
and intact leaf tissue of both stably and transiently transformed Gag-expressing 
plants.  In leaf extracts, enveloped VLPs with diameters of approximately 100 nm 
were visualized (Figures 21C, D, Figure 22E, F).  Similarly-sized particles could 
also be oveserved in situ in both transiently and stably expressed leaf tissue 
(Figure 21A, B, Figure 22A-D). VLPs were found in the apoplastic space between 
the cell wall and the plasma membrane (Figure 22C, D), but also within in 
intracellular compartments such as the vacuole (Figure 21A, B), in the lumen of 
cytoplasmic membrane vesicles (Figure 22B) and perhaps even in the cytoplasm 
itself (Figure 22A). 
Moreover, in tissues of plants that express the Gag protein (Figure 21A, 
B), but not in tissues from untransformed plants (data not shown), I observed 
electrodense patches on various cellular membranes that I interpreted as 
congregating Gag protein molecules during during the process of VLP budding 
across the plasma membrane out into the apoplastic space and across the  
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Figure 20. Trypsin digestion assay.  The first lane (from left) contains proteins 
from non-infiltrated wild type plant extract.  The remaining lanes contain VLP 
enriched samples from a transgenic Gag-expressing plant, incubated with or 
without Triton X-100 and/or trypsin.  When incubated with trypsin alone, the Gag 
is protected from proteolytic digestion by the membrane envelope, but when this 
envelope is disrupted with the addition of detergent (Triton X-100), the Gag is 
digested by the enzyme, suggesting that the Gag VLPs are fully enveloped. 
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Figure 21. Results of TEM in plants transiently expressing gag.  A and B.  
Representative sections from chemically fixed leaf tissue transiently expressing 
Gag VLPs, showing Gag VLPs (red arrows) budding from the vacuolar 
membrane into the vacuole.  C and D.  Representative negatively stained VLPs 
from leaf tissue extract of plants transiently expressing Gag protein.  Bar 
represents 100 nm.  
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Figure 22. Results of TEM in transgenic gag plants.  A - D.  Representative 
sections from chemically fixed transgenic gag leaf tissue showing VLP production 
accumulation (red arrows) in cytoplasm (A.), in endosomes near the vacuole (B.) 
and within the apoplastic space (C. and D.).  E and F.  Representative negatively 
stained VLPs from VLP enriched extract of transgenic gag leaves. Bar represents 
100 nm. 
  64 
vacuolar membrane into the vacuole lumen. Similar structures were observed in 
mammalian, insect and yeast cells that express Gag from HIV-1 and other 
lentiviruses. 
 VLPs from leaf tissue of plants co-expressing Gag and dgp41 were also 
observed in both leaf tissue and enriched VLP containing extracts, and these 
VLPs were morphologically similar to those found in the Gag-only expressing 
plants (data not shown). 
Protoplast Experiments 
 As described above, I observed by TEM the budding of HIV-1 Gag and 
Gag/dgp41 VLPs across cellular membranes. To further substantiate this 
observation, I wanted to actually collect such budded particles. However, due to 
the presence of cellulose cell walls surrounding plant cells, when VLPs bud from 
the plasma membrane of plant cells, I expected them to become trapped in the 
apoplastic space between the plasma membrane and the cell wall. I further 
hypothesized that such particles would be released if the constraint of the cell 
wall is removed.  To test this hypothesis, protoplasts were generated from 
transgenic Gag plants by enzymatically removing the cell walls and the culture 
medium was sampled every hour up to 6 h after protoplast isolation to check for 
presence of Gag protein (Figure 23).  Protoplasts remained intact for the duration 
of the 6 hours of incubation, and lysis was apparent only after longer incubation 
periods (data not shown).  I observed time-dependent accumulation of Gag 
protein in the protoplast medium (separated from the protoplasts by 
centrifugation). The initial supernatant (fresh buffer with newly isolated 
protoplasts) did not contain any Gag protein.  The presence of Gag was detected  
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Figure 23. Protoplast Assay. P – Pelleted protoplast cells showing total amount 
of Gag in cells.  0 -  initial protoplast buffer at  time point 0.  1-6 – hourly samples 
taken from protoplast supernatant.  Results show that Gag was able to bud from 
the cell after the cell wall was removed, possibly suggesting that the protein is 
forming VLPs that are able to bud from the plasma membrane. 
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at 2 h and their levels continued to increase as a function of the incubation time.  
Importantly, only intact Gag protein was found in the medium, whereas 
intracellular accumulation of the protein was always accompanied by the 
accumulation of truncated forms/degradation products. Specifically a 44 kD band 
was found in the cells but not in the incubation medium. These results strongly 
suggest that Gag, not a secretory protein, is released from the cells, probably in 
the form of VLPs that bud out of the plant plasma membrane into the medium.  
Taken together with the TEM pictures showing VLPs budding into the apoplastic 
space in vivo, it can be concluded that plant cells can support the formation and 
budding of HIV-1 Gag and also Gag/dgp41 VLPs. 
 
DISCUSSION 
 To date, the mechanisms behind VLP formation in plants has not been 
extensively studied.  Only a handful of plant viruses form enveloped virus-like 
particles  (Tas et al., 1977; Chu et al., 2001; Whitfield et al., 2004; Margaria et al., 
2007) and researchers have only recently begun to express animal virus VLPs.  
The field of plant-based VLP production is still in its youth, and extensive 
characterization of plant-produced VLPs and their assembly processes are 
needed in order to better understand how these particles are formed in plant 
cells.   
  Despite the lack of in planta characterization of either naturally occurring 
enveloped viruses or VLPs expressed using recombinant techniques, there is 
ample, albeit circumstantial, evidence that plants have the machinery needed for 
enveloped VLP production, which is supported by the fact that the 19 species of 
the enveloped plant-virus genus Tomspovirus have one of the widest ranges of 
  67 
hosts (over 800 plant species) of any plant-virus (Adkins et al., 2005; Pappu et 
al., 2009).  In addition to the existence of enveloped plant-viruses, many of the 
genes (and subsequent gene products) involved in the formation of enveloped 
viruses in mammals and other animals have homologs in plants.   
 Most eukaryotes have two NMT genes, and the Arabidopsis thaliana 
NMT1 has close sequence homology to animal NMTs (Podell and Gribskov, 
2004).  Several important plant enzymes such as calcium dependent protein 
kinases require myristoylation for proper function (Benetka et al., 2008), and as 
such, plants express several myristoylated proteins (A. thaliana has over 300) 
(Podell and Gribskov, 2004).  This evidence suggests that plants have the 
capability to myristoylate HIV-1 Gag protein and thus increase its membrane 
affinity and assist the formation of VLPs.  Although no Nicotiana NMT sequences 
have been characterized to date, presence of NMT activity in tobacco cells 
(Podell and Gribskov, 2004) and the ubiquitous nature of NMT genes throughout 
the plant kingdom implies that the genes within the genus would be sufficient to 
myristylate HIV-1 Gag and help target the protein to the plasma membrane. 
 PI(4,5)P2  in higher plants is found at levels 10 times lower than those 
found in animals and lower plants, but it seems to be important for vesicular 
trafficking and cytoskeleton regulation (Meijer and Munnik, 2003).  It becomes 
concentrated at the plasma membrane during certain conditions such as 
phospholipase C inhibition, salt stress, during the final stage of BY-2 cell division, 
and at the tips of growing root hairs (van Leeuwen et al., 2007).  When it is 
localized to the plasma membrane, it is mostly concentrated at membrane rafts 
(Furt et al., 2010).  Despite the low amounts of PI(4,5)P2 in plants, its existence in 
plants and the ability for it to concentrate at membrane rafts (where Gag and 
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other HIV-1 proteins localize during virus-formation) suggest that PI(4,5)P2 is 
able to interact with HIV-1 Gag when expressed in plants and thus assisting the 
formation of VLPs. 
 Plants contain orthologs for all major ESCRT complex subunits, which 
have varied endogenous functions due to vacuolar trafficking (Otegui and 
Spitzer, 2008).  Most of the research on the ESCRT pathway in plants has been 
performed in A. thaliana, which has orthologs of both Tsg101 and Alix (Spitzer et 
al., 2009).  Orthologs in N. benthamiana have not yet been fully characterized (ie. 
not fully sequenced), although some dominant mutant studies inhibited 
replication of tomato bushy stunt tombusvirus in N. benthamiana (Barajas et al., 
2009; Barajas and Nagy, 2010).  The endogenous ESCRT pathways within 
plants could aid in the budding of VLPs from plant cells into the apoplastic space 
between the cell wall and plasma membrane. 
 All of this evidence, paired with the eukaryote-common post-
transcriptional/translational features of plant cells, suggests that N. benthamiana 
is capable of expressing Gag-based VLPs that bud from the plasma membrane, 
but this had not been proven until this study.  Results suggest that Gag and gp41 
can be co-expressed together in plants where they assemble into VLPs that have 
the potential to be used as a mucosally-targeted HIV-1 subunit vaccine.  
 Immunogenic Gag VLPs have previously been produced in various 
eukaryotic expression systems including mammalian, insect, and yeast cells, but 
only two published studies have shown production of full-length Gag and Gag 
derivatives in N. benthamiana or N. tabacum {Meyers, 2008 #94; Scotti, 2009 
#92}  Both studies had very limited success with cytosolic expression, focusing 
instead on chloroplast expression of Gag.  Although Meyers et. al showed TEM 
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micrographs of their Gag VLPs, neither of the two groups fully characterized their 
expression products to support the formation of enveloped VLPs, which would be 
essential in the co-expression of Gag VLPs with envelope anchored proteins 
such as gp41. 
 This study is the first to fully characterize VLPs in N. benthamiana.  The 
results of density gradient sedimentation, trypsin digestion of delipidized Gag, 
and electron microscopy have all suggested that Gag is forming ~100 nm 
enveloped VLPs in N. benthamiana.  In addition to expressing Gag in plants, the 
co-expression of dgp41 with the Gag VLPs was also observed.  To my 
knowledge, this is the first study to show that Gag and dgp41 can be co-
expressed in plants.  In addition to co-expressing the two proteins, all of the 
above biochemical assays have suggested that the two proteins are assembling 
together into enveloped VLPs.  Based on these results, these VLPs could hold 
great promise for future studies involving Gag/dgp41 VLPs as potential vaccine 
candidates. 
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Chapter 4 
I.P. IMMUNIZATION OF MICE WITH GAG/DGP41 VLPS 
ABSTRACT 
 Gag VLPs expressed in a number of systems have been shown to elicit 
substantial antibody and CTL responses in mice, rabbits, and non-human 
primates, but the immunogenicity of plant-expressed VLPs (with or without 
surface-displayed Env proteins) had not been tested until this study.  An 
immunization trial involving systemic priming and boosting with plant-based HIV-
1 Gag/dgp41 VLPs was conducted in mice.  As will be presented, it was revealed 
that these plant-based HIV-1 Gag/dgp41 VLPs can elicit antibody responses 
against both Gag and MPER. 
 
INTRODUCTION 
 Substantial evidence is available for the immunogenicity of Gag, gp41, 
and chimeric Gag/Env VLPs expressed in insect and mammalian cell cultures.  
The MPER peptide has been tested in numerous immunological studies 
(reviewed in (McGaughey et al., 2004; Montero et al., 2008; Nieva et al., 2011)), 
with the overarching theme of these studies illustrating that while peptides of the 
MPER region are not immunogenic on their own, when expressed as a fusion 
protein with other more immunogenic proteins (ie. keyhole limpet hemocyanin, 
viral coat proteins, VLPs of influenza, CTB, etc.), high titers of neutralizing 
antibodies against the ELDKWA and NWFDIT epitopes can be elicited.   
 The Mor lab has focused on studies using MPR fused to the B subunit of 
cholera toxin (CTB) (Matoba et al., 2004; Matoba et al., 2006; Matoba et al., 
2008), plaque antigens F1 and V (Matoba et al., 2011), and hepatitis B core 
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antigen (HBc) (Cherni, 2008).  Three different studies by Matoba et al. describe 
the immunogenicity of E. coli-derived CTB-MPR  in both mice and rabbits 
(Matoba et al., 2004; Matoba et al., 2006; Matoba et al., 2008).  Initially, the 
fusion peptide was tested by mucosal priming followed by both mucosal and 
systemic boosts in mice.  This immunization scheme elicited strong serum IgG 
responses as well as vaginal and fecal IgA responses against the MPER peptide, 
although the mucosal response was relatively transient.  The antibodies 
produced in the trial were able to block transcytosis of HIV-1 virus across an 
epithelial barrier (Matoba et al., 2004).  The initial success with this immunogen 
lead to additional studies exploring the effectiveness of a heterologous prime-
boost strategy in which the effect of immunization route (systemic or mucosal) in 
priming and boosting strategies was explored (Matoba et al., 2006).  In 
congruence with the initial studies, significant transcytosis-blocking antibody 
titers against the MPER peptide were elicited from the immunizations.  It was 
determined that mucosal priming with adjuvant followed by systemic boosting 
elicited the best induction of anti-MPER antibodies, although antibodies against 
the CTB portion of the immunogen appeared to be dominant over anti-MPER 
responses.  In addition to the immunization studies conducted with E. coli-
produced CTB-MPR, a further trial was conducted using CTB-MPR expressed in 
transgenic plants.  In accordance with the previous two trials, serum and vaginal 
antibodies against MPER were elicited when mice were mucosally primed with 
plant-based CTB-MPR and systemically boosted with the same (Matoba et al., 
2009).  In congruence with the murine studies, transcytosis-blocking anti-MPER 
antibodies were elicited in rabbit serum.  Once again, however, the CTB portion 
of the immunogen seemed to be immunodominant.  Further characterization of 
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the antibody response revealed that although the antibodies could block HIV-1 
transcytosis, the antibodies were not able to neutralize virus in CD4-dependent 
infection in either a PBMC neutralization assay or a pseudovirus neutralization 
assay.   
 In order to counteract the immunodominace of the CTB portion of the 
CTB-MPR fusion peptide, additional fusion partners, F1-V of Yersina pestis and 
the Hepatitis B core antigen (HBc) were fused to MPER and tested for their 
immunogenicity in mice.  Similar to trials with CTB- MPR, F1-V-MPR induced a 
strong IgG response to the carrier molecule, but unfortunately only induced low 
titers of antibodies against the MPER moiety (Matoba et al., 2011).  When a 
heterologous prime-boost strategy using a priming immunization of CTB- MPR 
and boosting immunization of F1-V- MPR was utilized, significant antibody titers 
were elicited which could not be elicited with either immunogen alone.  These 
studies confirmed both the low immunogenicity of the MPR peptide and the 
effectiveness of a heterologous prime-boost strategy with more than one 
presentation of the MPER peptide (Matoba et al., 2011).  Further studies were 
conducted using VLPs formed by the fusion of a truncated hepatitis capsid 
protein with MPR (Cherni, 2008).  Unfortunately, only extremely low titers of 
serum IgGs were elicited from homologous prime-boost with the HBc- MPR 
VLPs, and the priming with HBc- MPR followed by a boost of CTB- MPR seemed 
no more effective than priming with control HBc protein.  The lack of 
immunogenicity against MPER of the HBc- MPR VLPs could be due to a number 
of factors including the lack of presentation of MPER in a suitable manner for 
immune recognition, immunodominance of the HBc VLP, and/or lack of 
optimization of adjuvant (Cherni, 2008).  All of these studies employing fusion 
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peptides with the MPER confirm the low immunogenicity of MPER on its own, the 
success of heterologous prime-boost strategies with multiple routes of 
immunization and more than one vaccine construct, and the promise of 
producing transcytosis-blocking antibodies from vaccine candidates utilizing the 
MPER of HIV-1 gp41.  Despite the success of some of these constructs, 
additional platforms with which to display the MPER peptide (preferably in a 
native conformation) are needed to combat the immunodominance of the tested 
fusion partners and to increase the immune response against MPER through 
heterologous construct strategies. 
 In addition to the MPER region of gp41, the cytoplasmic tail domain 
(CTD) of gp41 has also been shown to play a key role in immunological studies.  
Despite the fact that the CTD resides below the surface of the virus membrane, 
there are still several mAbs that recognize the “Kennedy epitope” (amino acids 
724-745, PRGPDRPEGIEEEGGERDRDRS), a hydrophilic region at the N 
terminus of the CTD (Buratti et al., 1998; Cleveland et al., 2000; Montero et al., 
2008). 
 The immunogenicity of HIV-1 Gag VLPs has also been extensively 
studied.  The Gag protein of HIV-1 has been shown to produce VLPs in various 
eukaryotic expression systems including mammalian (Rovinski et al., 1992), 
insect (Buonaguro et al., 2002; Deml et al., 2004; Buonaguro et al., 2005; 
Tagliamonte et al., 2010, 2011; Visciano et al., 2011), and yeast cell cultures 
(Sakuragi et al., 2002).  Many of these particles were tested in immunogenicity 
studies in mice, rabbits, and non-human primates (Doan et al., 2005).  Humoral 
immune responses induced by priming with Gag VLPs was shown in rabbits 
(Wagner et al., 1996a; Deml et al., 2005) and rhesus macaques (Montefiori et al., 
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2001).  In rabbits, intramuscular (i.m.) injection of baculovirus-derived VLPs 
elicited strong anti-Gag antibodies, but these antibodies were non-neutralizing.  
In a second animal model, rhesus macaques were inoculated with VLP in QS21 
adjuvant with similar results to the rabbit trials (Montefiori et al., 2001).  In 
contrast, long-lived CD8+ cytotoxic T-cell (CTL) responses against multiple 
epitopes of the Gag protein were stimulated in rhesus macaques when the VLPs 
were inoculated without adjuvant (Paliard et al., 2000).   
 In addition to the immunogenicity of Gag alone, Gag VLPs have been 
able to display HIV-1 Env proteins either as fusion proteins (Wagner et al., 1993; 
Wagner et al., 1994b; Brand et al., 1995b; Brand et al., 1995a; Truong et al., 
1996) or on their surface in their native conformation (Haffar et al., 1990; Vzorov 
et al., 1991; Rovinski et al., 1992; Krausslich et al., 1993; Wagner et al., 1993; 
Rovinski et al., 1995; Deml et al., 1997b; Deml et al., 1997a; Hicar et al., 2010).  
When Gag was displayed as VLPs fused to Env proteins, the VLPs still elicited 
anti-Gag antibodies and CTL responses, but immune response against the fused 
Env proteins was fairly low (Deml et al., 2005).  In contrast, when various Env 
peptides were displayed in their native conformation, successful humoral and 
cellular immune responses against Gag and the displayed Env protein were 
elicited in both rodents (Haffar et al., 1990; Rovinski et al., 1992; Rovinski et al., 
1995; Wagner et al., 1996b; Deml et al., 1997b; Deml et al., 1997a; Buonaguro et 
al., 2002) and non-human primates (Wagner et al., 1998).  Several types of 
Gag/Env VLPs have been able to elicit significant titers of Env-specific antibodies 
which were able to neutralize homologous (Rovinski et al., 1995; Deml et al., 
1997b; Deml et al., 1997a) and heterologous virus isolates (Buonaguro et al., 
2002), the activity of which largely corresponded to the quantity of Env particles 
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that were incorporated into the VLPs.  In addition to eliciting antibodies against 
Gag and Env, significant Gag- and Env- specific CD8+ CTL activities were 
observed in mice (Deml et al., 1997b; Deml et al., 1997a) and non-human 
primates (Wagner et al., 1998). 
 Although all of this evidence of immunological success of Gag and 
Gag/Env VLPs is promising, very little immunological data is available for plant-
based HIV-1 full-length Gag or gp41 vaccine antigens.  Promisingly, the little 
information that has been garnered from the limited studies shows potential for 
success.  Although the lack of substantial expression of HIV p55 Gag in plants 
precludes its use in immunological studies, many trials have been performed with 
derivatives of Gag (ie. p24, p17, and p41) with great success in the elicitation of 
strong anti-p24 and p17 antibodies as well as CTL response (Perez-Filgueira et 
al., 2004; Guetard et al., 2008; Iglesias et al., 2008; Mahdavi et al., 2010; 
Gonzalez-Rabade et al.).  There have also been several studies showing 
immunological responses against plant-based gp41 constructs (McLain et al., 
1995; McLain et al., 1996; Durrani et al., 1998; McInerney et al., 1999; Marusic et 
al., 2001; Matoba et al., 2009).  Two different studies focused on epitopes in the 
MPER of gp41.  As described earlier, a murine trial was conducted by Matoba et 
al. using CTB-MPR expressed in transgenic plants.  This construct elicited serum 
and vaginal antibodies against MPER when mice were mucosally primed with 
plant-based CTB-MPR and systemically boosted with the same (Matoba et al., 
2009).  One other group has tested the immunogenicity of plant-based portions 
of the MPER.  Marusic et al. fused the ELDKWA epitope (recognized by the 2F5 
neutralizing antibody) to the coat protein of potato virus X, expressed the 
construct in N. benthamiana, and used it to immunize mice.  The construct was 
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able to elicit HIV-1 neutralizing antibodies when administered mucosally and 
intraperitoneally (Marusic et al., 2001).  Portions of the cytoplasmic tail of gp41 
(a.a. 731-752) have also been expressed in plants via insertion into the S protein 
of cowpea mosaic virus (CPMV) and were shown to be immunogenic in several 
trials (McLain et al., 1995; McLain et al., 1996; Durrani et al., 1998; McInerney et 
al., 1999).  Through a series of subsequent trials exploring the effects of 
immunization route and use of several different adjuvants, it was determined that 
the CPMV-HIV/1 particles utilizing gp41 a.a. 731-752 could elicit neutralizing 
antibody titers in mice.  It was established that a nasal immunization route was 
more effective than oral immunization (Durrani et al., 1998), and that the adjuvant 
Quil A was most effective in eliciting immune responses in subcutaneous 
immunizations (McInerney et al., 1999).  
 The overwhelming evidence that Gag/Env VLPs can elicit both 
neutralizing antibodies and CTL responses is promising for the development of 
Gag/Env VLPs for use as vaccine candidates against HIV-1.  The few plant-
based vaccine candidates that have been tested for immunogenicity have 
showed promise equal to those produced in other cell culture systems, and as 
will be presented in this chapter, immunization trials employing plant-based HIV-
1 Gag/dgp41 VLPs confirm these previous results. 
 
MATERIALS AND METHODS 
Plant-based VLP Purification 
Purification of VLPs for immunization trials was performed in 20 gram 
batches.  Twenty grams of leaves expressing Gag/dgp41, which had been stored 
at -80°C, were crushed with liquid nitrogen into powder and added to plant 
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extraction buffer (60 ml, 25 mM Na2HPO4/NaH2PO4, 100 mM NaCl, 1 mM 
ethylenediaminetetraacetic acid (EDTA), pH 7.8) and shaken on ice for 60 min.  
The mixture was then strained through miracloth to remove pulp and centrifuged 
at 14,000 g for 20 min to clarify the extract.  Ammonium sulfate was added to 
clarified extract to 40% and the extract was shaken on ice for 60 min to 
precipitate VLPs.  The extract was then centrifuged at 36,000 rpm for 30 min to 
pellet the VLPs.  Pelleted VLPs were resuspended in PBS (4 ml) and layered on 
top of two 30% Optiprep cushions (from bottom, 1 ml 50% iodixanol, 2 ml 30% 
iodixanol, 7 ml 20% iodixanol, 2 ml VLP extract) and spun at 35,000 rpm in an 
SW41Ti rotor (Beckman-Coulter) for 5 h.  The 30% iodixanol fraction (2 ml each) 
was collected and concentrated with a 300 kD-cutoff centricon.  Quantifications 
of both Gag and gp41 were determined with quantification immunoblots as 
previously described. 
E. coli-based CTB-MPR Expression and Purification 
Expression of the CTB-MPR fusion protein in E. coli and its purification 
was done as previously described (Matoba et al., 2008).  Briefly, E. coli cultures 
containing pTM 199 were grown from single colonies overnight at 37°C.  
Logarithmic phase cultures were induced with 100 μM isopropyl β- D -1-
thiogalactopyranoside (IPTG) and allowed to grow for 2 h before centrifugation of 
the cells.  Cell pellets were resuspended in PBS (20 ml) and lysed by 
microfluidization.  Lysed cells were pelleted by centrifugation, and the insoluble 
pellet was solublized in CHAPS buffer (80 mM Tris, 2 M NaCl, 1.5% (w/v) 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), pH 8.0), 
rocked at 4°C for 60 min, and then centrifuged to remove the remains of the 
insoluble cell fractions.  The soluble supernatant was then added to a 25 ml 
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Talon gravity flow column and purified by metal affinity chromatography.  The 
final column eluate (50 ml) was dialyzed in PBS with a 3.5 kD-cutoff membrane 
for 24 h to remove CHAPS and imidizole, and then centrifuged at 2,000 g for 20 
min to pellet the CTB-MPR.  Pelleted protein was collected, washed 2x with PBS, 
and resuspended in sterile PBS (500 µl).  Purity and quantification of the pure 
CTB-MPR was determined by Coomassie stained gels, quantitative immunoblots 
(using a pure standard), and by determining the absorbance at 280 nm using (ɛ = 
2.1 mM-1 cm-1).    
Immunizations 
 The experimental protocol involving animals was approved by the 
Institutional Animal Care and Use Committee of Arizona State University.  
Female BALB/c mice (6-wk old, Charles River) were immunized intraperitoneally 
(i.p.) with 200 μl of CTB-MPR (3.5 μg, including 1.2 μg MPER), purified VLPs 
(1.2 μg MPER, 2.1 μg p24, 111 μg total plant protein), or wild-type plant protein 
(100 μg prepared in the same manner as the VLP proteins).  Each concentrated 
protein was mixed with PBS and ribi adjuvant (Sigma) to a final concentration of 
2% oil as per manufacturer‟s instructions.  Four experimental groups (n=8) were 
given either VLP or CTB-MPR during each of three priming immunizations, and 
were then given either VLP or CTB-MPR during each of two boosting 
immunizations (Table 6).  As a negative control, a fifth group was immunized with 
wild-type plant protein for each of the five immunizations.  Serum was collected 
from all mice in two week intervals through the end of the trial. 
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Table 6. Immunization schedule for i.p. immunizations.  
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Antibody Titer Assays 
ELISA plates were coated with 20 μg of streptavidin (Sigma) and 2 μg of 
biotinylated MPER peptide (for detection of MPER antibodies (Matoba et al., 
2006)) or 1 μg of p24-CTA2.  Threefold serial dilutions of serum starting from  
1:50 were applied on to the plates and incubated for 1 h at 37°C.  Serum IgGs 
were detected by peroxidase conjugate of anti-mouse IgG (Calbiochem).  
Endpoint titers were determined by standard curve, using the reciprocal of the 
dilution factor of sample giving background levels of OD490.   
Transcytosis Assays 
Transcytosis assays were performed by the lab of Morgane Bomsel at the 
Institute Cochin in Paris, France as described (Bomsel et al., 1998; Alfsen et al., 
2001).  Epithelial cells were grown as a confluent monolayer on permeable 
support (Figure 24).  Samples of Ig were partially purified by ammonium sulfate 
(0-50% saturation fraction) and then dialyzed against RPMI medium 1640, 10% 
FCS.  Cells (106/40µl) infected with HIV-1NDK were incubated at the apical pole 
of epithelial cells.  Transcytosis was allowed to proceed for 110 min at 37°C.  
Viral load in the basolateral chamber was estimated from the p24 content (p24 
kit, Coulter).  Transcytosis was expressed as percentage of control.   
Neutralization Assays 
Neutralization assays were performed by the lab of Nobuyuki Matoba at 
the Owensboro Cancer Research Center in Owensboro, KY as previously 
described (Figure 25)  (Montefiori, 2009; Matoba et al., 2010).  Env-pseudotyped 
viruses were prepared by co-transfection of 293T/17 cells with various env-
expressing plasmids and an env-deficient HIV-1 backbone vector (pSG3ΔEnv)   
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Figure 24.  Model of epithelial transcytosis assay.  Epithelial cells were grown as 
a confluent monolayer on permeable support.  Partially purified samples of Ig 
were incubated with HIV-1 NDK-infected cells at the apical pole of epithelial cells.  
HIV-1 specific antibodies (in orange) bound to the virus prevented the 
transcytosis of virus across the epithelial cell layer.  Amount of virus transcytosis 
was measured by p24 ELISAs.  
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Figure 25.  Pseudovirion neutralization assay. On top are schematic diagrams of 
expression vectors used in this assay. The envelope-defective, provirus clone (1) 
is shown above the vector that expresses an intact env gene of the virus of 
interest (2). Both vectors are used for co-transfection of 293T cells (3), which are 
allowed to produce pseudovirions that are then harvested (4). Neutralization is 
carried out by incubating the harvested pseudovirions for 1 hour in the presence 
of serial dilutions of Ab preparations (5). Finally, residual pseudovirions are 
allowed to infect target (CD4+/CCR5+) cells (6). Single round of infection results 
in cells, which express the luciferase reporter gene (and the  galactosidase) and 
the resultant luminescence is measured (7).  
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and were titrated in TZM-bl cells to determine the 50% tissue culture infective 
dose (TCID50). Antiviral activity was expressed as an IC50 value, which is the 
sample concentration giving 50% of relative luminescence units (RLUs) 
compared with those of virus control after subtraction of background RLUs.  The 
broadly neutralizing mAbs b12, 2G12, 2F5 and 4E10, as well as soluble CD4 
were used as positive controls. Two-hundred TCID50 of pseudoviruses were used 
for the neutralization assay. Samples and the virus were mixed and incubated for 
1 h at 37°C, to which 104 cells/well of TZM-bl cells were added and incubated for 
72 h. Luciferase activity was measured using the Britelite Plus Reagent 
(PerkinElmer, Waltham, MA).  
 
RESULTS 
Antibody Titers Against p24 
 The average OD490 (Figure 26) and endpoint titers (Figure 27) were 
calculated after the third priming immunization (Week 6), before the first boost 
(Week 8), after the first boost (Week 10), and after the second boost (Week 12) 
for antibodies against p24.  In both groups primed with VLPs, very significant 
antibody titers (p < 0.01, in comparison to the negative control group) were 
elicited after priming and remained at those levels until the first boost.  The VLP 
priming groups were then split into two groups, with one boosted with CTB-MPR 
and the other boosted with VLPs.  The group primed with CTB-MPR retained 
significant titers of anti-p24 antibodies through the end of the trial, despite the 
fact that the mice did not receive any further Gag protein.  Boosting with VLPs 
resulted in increased antibody titers, with final antibody titers reaching extremely  
  84 
 
 
 
Figure 26. Serum anti-p24 and anti-MPER IgG levels.  Mice were immunized as 
per Table 6.  Serum samples were diluted 1:50 and IgGs were detected by direct 
ELISA on indicated weeks.  Shown are average net OD490 values (mean +/- 
SEM).  Mouse #3 (from CTBMPR-CTBMPR group) responded significantly 
higher than other mice from this group and was considered an outlier, and 
antibody response from this mouse is shown by itself.    
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Figure 27. Serum anti-p24 IgG levels.  Ab endpoint titers at response peaks after 
priming (Week 6), before first boost (Week 8), after first boost (Week 10), and 
after second boost (Week 12). Symbols indicate statistical significance as 
compared to week zero within the group evaluated by Kruscal-Wallis test and 
Dunn‟s Multiple Comparison test: * p < 0.05, ** p < 0.01, *** p < 0.001. 
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significant (p< 0.001) values over the negative control mice.  In mice primed with 
CTB-MPR and then boosted with VLPs, anti-p24 antibody levels corresponding 
to the first two priming immunizations of the VLP priming groups were elicited, 
and these titers were very significant (p < 0.01, in comparison to pre-boost levels) 
following the second boost.  All of these data advocate that plant-produced VLPs 
can elicit robust, long-lived antibody responses against the Gag protein after only 
two immunizations.     
Antibody Titers against MPER 
 The average OD490 (Figure 26) and endpoint titers (Figure 28) were 
calculated after the third priming immunization (Week 6), before the first boost 
(Week 8), after the first boost (Week 10), and after the second boost (Week 12) 
for antibodies against the MPER region of gp41.  In mice primed with CTB-MPR, 
11/16 mice responded to the MPER moiety before the second boost.  One of 
these mice (#3 from the CTBMPR primed and boosted group) responded 
significantly more than the rest of the mice, and as such, the response of this 
mouse is shown on its own in Figure 24.  In mice primed with VLPs, 7/16 mice 
responded to the MPER portion of dgp41.  Boosting of the CTB-MPR primed 
group with CTB-MPR elicited very significant (p < 0.01) titers of anti-MPER 
antibodies after the second boost, which continued to increase after the second 
boost to extremely significant titers (p < 0.001) with 8/8 mice responding.  
Boosting the CTB-MPR primed group with VLPs elicited very significant titers as 
well with 8/8 mice responding, and though antibody titers did not reach the levels 
of the CTB-MPR boosted group, the difference between boosting groups was not 
significant.  In mice primed with VLPs and boosted with CTB-MPR, extremely 
significant titers of anti-MPER antibodies were elicited compared to priming  
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Figure 28. Serum anti-MPER IgG levels.  Ab endpoint titers at response peaks 
after priming (Week 6), before first boost (Week 8), after first boost (Week 10), 
and after second boost (Week 12).  Symbols indicate statistical significance as 
compared to week zero within the group evaluated by Kruscal-Wallis test and 
Dunn‟s Multiple Comparison test: * p < 0.05, ** p < 0.01, *** p < 0.001.  
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immunizations, with 8/8 mice responding after the second boost.  In mice primed 
with VLPs and boosted with VLPs, significant (p< 0.05) titers were raised after  
the first boost, which continued to increase to very significant (p< 0.01) titers 
following the second boost, with 7/8 mice responding.  All four experimental 
groups elicited statistically significant antibody levels following the second boost, 
and while the group given CTB-MPR in both priming and boosting immunizations  
had slightly higher titers than the other groups, the remaining three groups 
utilizing either both CTB-MPR and VLPs or only VLPs elicited titers very similar 
to each other at the end of the second boost, and all four groups were not 
statistically different from each other. 
Neutralization Assays 
 Mouse serum from the best responders was sent to collaborators for 
neutralization assays and I am currently awaiting results of these assays.   
Transcytosis Assays 
 Mouse serum from each of the mice in the trial was sent to collaborators 
for performing transcytosis assays and I am currently awaiting results of these 
assays.   
 
DISCUSSION 
 The immunogenicity of HIV-1 Gag/Env VLPs has been established in a 
number of animal trials in the past, but the immunogenicity of plant-expressed 
HIV VLPs (with or without surface-displayed Env proteins) had not been tested 
until this study.  As presented above, HIV-1 Gag/dgp41 VLPs produced in N. 
benthamiana were able to elicit substantial titers of antibodies against both Gag 
and gp41 epitopes.   
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 Much can be learned from this first trial with plant-based HIV-1 VLPs.  
The MPER peptide has been expressed in E. coli and plants before as a fusion 
peptide with CTB and shown to be immunogenic in mice in both cases (Matoba 
et al., 2004; Matoba et al., 2006; Matoba et al., 2009).  Although only modest 
levels of anti-MPER antibodies were elicited through the trials, these antibodies 
possessed neutralization ability, suggesting that MPER could play an important 
role as a viable component of a vaccine candidate.  Despite the relative success 
of the vaccine candidate, immunodominance of the CTB moiety presented an 
immunological challenge.  It was hypothesized that this immunodominance could 
be combated by the development of additional fusion constructs including those 
utilizing peptides from Yersinia pestis (F1-V) or the Hepatitis B core antigen 
(HBc).  Unfortunately, neither of these constructs elicited significant titers of anti-
MPER antibodies, but instead further demonstrated the low immunogenicity of 
the MPER peptide.  Once again, titers against the carrier peptide moiety of the 
fusion proteins continued to express immunodominance. 
 Since HIV-1 Gag had been shown to display HIV-1 Env proteins on their 
surface in native confirmation and been shown to be immunogenic against both 
the Gag and Env proteins, it was hypothesized that if enveloped particles made 
of Gag displaying a deconstructed gp41 consisting of the MPER region, 
transmembrane domain, and cytoplasmic tail could be expressed in plants, then 
they would also be immunogenic.  If the particles were found to be immunogenic, 
then they could present possible solutions to the limitation of the CTB-MPR 
fusion candidate. 
 As was presented, plant-based VLPs did elicit an immune response when 
used as the vaccine antigen in either priming or boosting injections in either 
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homologous or heterologous platform prime-boosts in conjunction with CTB-
MPR.  Highly significant levels of antibodies were raised against the MPER 
region of gp41 after boosting with VLPs.  These levels of antibodies were robust, 
continuing to rise throughout the course of the study without the taper evident in 
antibody levels raised by mice primed and boosted with CTB-MPR alone 
(confirming a phenomenon observed in previous studies (Matoba et al., 2006)), 
suggesting that antibodies produced by VLPs are long-lived.  The levels of 
antibody titers after the second boost were not significantly different between 
groups primed or boosted with CTB-MPR, suggesting that VLPs can be as 
effective as CTB-MPR in eliciting an anti-MPER response. 
 In addition to the elicitation of anti-MPER antibodies, extremely significant 
titers of antibodies specific to the Gag protein were also elicited in groups that 
were either primed or boosted with the VLPs.  Every mouse (16/16) that was 
primed with VLPs elicited a strong antibody response at the end of the three 
priming immunizations, with many responding as early as two weeks after the 
first priming immunization (Figure 26).  These antibodies remained high 
throughout the remainder of the study even when mice were boosted with a 
construct that did not contain Gag, but two boosters with VLPs were successful 
in boosting the antibody titers of these mice.  In addition, several (5/8) mice 
primed with CTB-MPR and boosted with VLPs elicited anti-p24 antibodies in 
levels that corresponded to the first two priming immunizations with VLPs, 
suggesting that if the trial had been extended, these titers would have continued 
to rise.  Although the IgG subtypes of these antibody responses was not yet 
analyzed, the anti-Gag antibodies elicited in this trial represent an important 
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immune response against HIV-1, as the induction of a humoral response against 
the polyprotein could induce a protective response against the virus.   
 At the current time, results of functional assays assessing the quality of 
antibodies produced in this trial are not available, although these experiments are 
currently in progress by collaborators.  Past results of trials utilizing VLPs and 
MPER peptides in other systems show that the antibodies raised against Gag 
and Env are able to block transcytosis of and neutralize HIV-1 virus.  While 
results are not confirmed yet, the relatively high titers of antibodies raised against 
both of these proteins is promising, and could suggest that antibodies produced 
in this trial will also be successful in functional assays. 
 Overall, the results of this trial show that plant-produced VLPs can elicit 
significant titers of antibodies against both Gag and gp41 proteins.  These results 
are promising, and inspire the use of these particles in additional immunization 
experiments with varied routes of immunization, which will be discussed in 
Chapter 5. 
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Chapter 5 
MUCOSAL IMMUNIZATION OF MICE WITH GAG/DGP41 VLPS 
 
ABSTRACT 
 Heterologous prime-boost immunizations, in which the route of 
immunization and/or the platform with which an antigen is displayed differ 
between the priming and boosting immunizations, have been shown to enhance 
the immune response versus a homologous immunization scheme.  In this 
chapter, the success of a heterologous prime-boost strategy utilizing two different 
antigen displays of MPER as well as both mucosal and systemic routes of 
immunization will be explored. 
 
INTRODUCTION 
 Decades worth of research have been conducted to no avail in the 
immense search for a prophylactic HIV-1 vaccine, but recent results of clinical 
trials have given researchers newfound hope in the development of an effective 
vaccine.  In the most promising clinical trial to date, the RV 144 trial conducted in 
Thailand, a heterologous prime-boost strategy using priming injections of a 
recombinant canarypox vector vaccine (ALVAC-HIV [vCP1521]) expressing Env, 
Gag, and protease plus two booster injections of a recombinant glycoprotein 120 
subunit vaccine (AIDSVAX B/E) was employed for modest protection against 
HIV-1 (Rerks-Ngarm et al., 2009).  In clinical trials involving only one of the 
components of the vaccine, no significant protection was inferred (Pitisuttithum et 
al., 2006), which has lead researchers to investigate the reasons behind the 
success of the trial (Johnston and Fauci, 2011).  Many researchers believe that 
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the protection could be due to the heterologous prime-boost administration of the 
vaccine components (Benmira et al., 2010).   
 The repeated use of the same vector or platform with which the vaccine is 
administered during priming and boosting (ie. same viral vector for DNA vaccines 
or fusion partner for peptide-based vaccines) can induce a strong immune 
response against the vector or fusion partner, and overpower immune response 
against the target antigen (Brown et al., 2010).  The immunodominance of the 
cholera toxin B-subunit (CTB) moiety in Matoba et al.‟s CTB-MPR candidate is 
an example of this challenge (Matoba et al., 2004; Matoba et al., 2006; Matoba et 
al., 2008; Matoba et al., 2011).  The dominant immune response against 
adenovirus-based vaccine vectors (Sumida et al., 2005), might have contributed 
to the failure of Ad5-based HIV-1 vaccines large-scale clinical trials such as the 
Step Study (Buchbinder et al., 2008).  Although such examples of the 
immunodominance of carrier proteins and vectors are widespread (Brown et al., 
2010), this recognition and response to the vectors and carrier proteins can be 
combated with a prime-boost strategy.  By utilizing multiple vectors and/or protein 
presentations, immune response can be targeted away from these supporting 
platforms and directed instead to the intended vaccine component.   
 Heterologous prime-boost immunizations, vaccine regimens that employ 
different target antigens, delivery vehicles, and immunization routes throughout 
the course of vaccination, have seen great success across the field of HIV 
vaccinology over the past decade (reviewed in (Lu, 2009; Radosevic et al., 2009; 
Brown et al., 2010; Paris et al., 2010)).   
 In addition to the use of multiple antigens and/or antigen presentation, it 
has been accepted that a wholly systemic immunization strategy that lacks a 
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mucosal component is not sufficient for inducing sustained mucosal responses, 
even though they are able to elicit systemic T-cell responses (Ranasinghe and 
Ramshaw, 2009).  In previous studies in the Mor lab examining the 
immunogenicity of the MPER peptide, it was discovered that a heterologous 
prime-boost strategy in which one immunogen was given either mucosally or 
systemically during priming, and then given as either mucosal or systemic 
injections during boosting immunizations, was more successful in eliciting a 
mucosal response than a single route of immunization (Matoba et al., 2006).  In 
previous studies, it was determined that mucosal priming with adjuvant followed 
by systemic boosting elicited the best induction of anti-MPER antibodies.  These 
data, in which E. coli-derived CTB-MPR was utilized, were supported by a 
second heterologous prime-boost trial involving mice mucosally primed with 
plant-based CTB-MPR and systemically boosted with the same (Matoba et al., 
2009).  As with the case of multiple vaccine platforms, the multiple routes of 
immunization are gaining impetus through the success of recent trials exploiting 
this strategy (Ranasinghe and Ramshaw, 2009). 
 It was previously shown (Chapter 4) that plant-based Gag/dgp41 VLPs 
are effective in eliciting immune responses when delivered systemically.  In order 
to engage the mucosal system, mucosal immunization was employed to test the 
efficacy of a heterologous prime-boost strategy comparing the mucosal priming 
of two separate antigen displays with systemic boosting of either a homologous 
or heterologous antigen display platform. 
 
MATERIALS AND METHODS 
Plant-based VLP Enrichment 
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Plant-based VLPs for immunization trials were purified from leaves of 
transgenic plants expressing Gag/dgp41 that were snap frozen in liquid nitrogen 
and kept at -80°C in 20 g batches.  Each batch was separately crushed with 
liquid nitrogen into a powder using a mortar and pestle and then suspended in 
plant extraction buffer (60 ml, 25 mM Na2HPO4/NaH2PO4, 100 mM NaCl, 1 mM 
ethylenediaminetetraacetic acid (EDTA), pH 7.8).  Following shaking the 
suspension for 60 min on ice, it was then strained through miracloth to remove 
solid particles and centrifuged at 14,000 g for 20 min.  Ammonium sulfate was 
added to clarified extract to 40% and shaken on ice for 60 min to precipitate 
VLPs.  The extract was then centrifuged at 36,000 rpm for 30 minutes to pellet 
the VLPs.  Pelleted VLPs were resuspended in PBS (4 ml) and layered on top of 
two 30% Optiprep cushions (from bottom, 1 ml of 50% iodixanol, 2 mls 30% 
iodixanol, 7 mls of 20% iodixanol, 2 mls VLP extract) and spun at 35,000 rpm in 
an SW41Ti rotor (Beckman-Coulter) for 5 h.  The 30% iodixanol fraction (2 mls 
each) was collected and concentrated with a 300 kD-cutoff centricon.  
Quantifications of both Gag and gp41 were determined with quantification 
immunoblots as previously described. 
E. coli-based CTB-MPR Expression and Purification 
Expression of the CTB-MPR fusion protein in E. coli and its purification 
was performed as previously described (Matoba et al., 2008).  Briefly, E. coli 
cultures containing pTM 199 were grown from single colonies overnight at 37°C.  
Logarithmic phase cultures were induced with 100 μM isopropyl β- D -1-
thiogalactopyranoside (IPTG) and allowed to grow for 2 h before centrifugation of 
the cells.  Cell pellets were resuspended in PBS (20 ml) and lysed by 
microfluidization.  Lysed cells were pelleted by centrifugation, and the insoluble 
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pellet was solublized in CHAPS buffer (80 mM Tris, 2 M NaCl, 1.5% (w/v) 
CHAPS, pH 8.0), rocked at 4°C for 60 min, and then centrifuged to remove the 
remains of the insoluble cell fractions.  The soluble supernatant was then added 
to a 25 ml Talon gravity flow column and purified by metal affinity 
chromatography.  The final column eluate (50 ml) was dialyzed in PBS with a 3.5 
kD-cutoff membrane for 24 h to remove CHAPS and imidizole, and then 
centrifuged at 2,000 g for 20 min to pellet the CTB-MPR.  Pelleted protein was 
collected, washed 2x with PBS, and resuspended in sterile PBS (500 µl).  Purity 
and quantification of the pure CTB-MPR was determined by Coomassie stained 
gels, quantitative immunoblots (using a pure standard), and by determining the 
absorbance at 280 nm using (ɛ = 2.1 mM-1 cm-1).    
Immunizations 
 The experimental protocol involving animals was approved by the 
Institutional Animal Care and Use Committee of Arizona State University.  
Female BALB/c mice (6-wk old, n=8 per group) were given four intranasal (i.n.) 
priming immunizations with CTB-MPR (35 μg, containing 12 μg MPER) with 
cholera toxin (CT) (1 μg), purified VLPs (containing 12 μg MPER, 21 μg p24) with 
CT (1 µg), or purified VLPs (containing 12 μg MPER, 21 μg p24) with murabutide 
(200 µg) (Table 7).  One group was given four intraperitoneal (i.p.) priming 
immunizations with purified VLPs (1.2 μg MPER, 2.1 μg p24) with ribi adjuvant 
(Sigma-Aldrich).  All mice were given two i.p. boosting immunizations with either 
CTB-MPR (3.5 μg, containing 1.2 μg MPER) or purified VLPs (1.2 μg MPER, 2.1 
μg p24) (Table 7).  Serum, vaginal secretions, and fecal pellets were collected 
from all mice on indicated days through the end of the trial.  Fecal pellets were 
prepared by soaking five pellets (~50 mg) in PBS containing 0.02% Na-azide 
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Table 7.  Mucosal immunization schedule. 
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(500 µl) for 30 min at 4°C with occasional vortex and clarification by 
centrifugation at 12,000 rpm for 10 min.  Vaginal secretions were collected by 
lavaging using PBS (100 μl) with a blunt-tipped syringe needle.   
Antibody Titer Assays 
ELISA plates were coated with 20 μg of streptavidin (Sigma-Aldrich) and 
2 μg of biotinylated MPR peptide (for detection of MPER antibodies) or 1 μg of 
p24-CTA2.  Threefold serial dilutions starting from 1:50 for serum, 1:5 for  
vaginal secretions, and 1:2 for fecal extract in PBS containing 0.5%Tween 100 
and 5% dry milk (PBSTM) were applied on to the plates and incubated for 1 h at  
37°C.  Serum IgGs and IgAs were detected by peroxidase conjugate of anti-
mouse IgG (Calbiochem) and anti-mouse IgA (Sigma), respectively.  Endpoint  
titers were determined as the reciprocal of the dilution factor of sample giving 
background levels of OD490.   
IFN-γ ELISPOT Assay 
 Splenocytes were prepared from spleens harvested on week 12 and 
pooled from 8 mice per group.  Interferon-gamma (IFN-γ) Enzyme-Linked 
Immunosorbent Spot Assay (ELISPOT) responses were measured using a 
mouse IFN-γ set (BD Biosciences).  Threefold serially diluted triplicates of 
splenocytes (starting at 1 x 106 splenocytes/well) were applied to the plates in a 
final volume of 200 µl RPMI 1640 culture medium (with 10% heat inactivated 
fecal bovine serum, 100 U/ml penicillin, 100 µg streptomycin).  The peptides 
AAMQMLKDTINEEAA (corresponding to the GagCD8 epitope, from HIV-1 
Consensus C Gag (15-mer) Peptides, Cat#8118, NIH AIDS Reagent Program) 
and SNPPVPVGDIYKRWI/VPVGDIYKRWIILGL (corresponding to the GagCD4 
epitope, from HIV-1 Consensus C Gag (15-mer) Peptides, Cat#8118, NIH AIDS 
  99 
Reagent Program) were used as stimuli in the assay at a final concentration of 5 
µg/ml.  Reactions without peptide served as background controls.  Reactions 
were allowed to proceed for 30 h at 37°C in a humidified 5% CO2 atmosphere.  
Spots were detected with the detection antibody, developed with 3-amino-9-
ethyl-carbazole (AEC Substrate Set; BD Biosciences), and analyzed using 
the CTL ImmunoSpot plate reader and counting software (Cellular 
Technology Ltd.).  For each group of mice, the number of background spots in 
the absence of peptide was subtracted from the average of the triplicate values in 
order to determine the number of peptide-relevant spots. 
Transcytosis Assays 
Transcytosis assays were performed by the lab of Morgane Bomsel at the 
Institute Cochin in Paris, France as described (Bomsel et al., 1998; Alfsen et al., 
2001).  Epithelial cells were grown as a confluent monolayer on permeable 
support (Figure 24).  Samples of Ig were partially purified by ammonium sulfate 
(0-50% saturation fraction) and then dialyzed against RPMI medium 1640, 10% 
FCS.  Cells (106/40µl) infected with HIV-1NDK were incubated at the apical pole 
of epithelial cells.  Transcytosis was allowed to proceed for 110 min at 37°C.  
Viral load in the basolateral chamber was estimated from the p24 content (p24 
kit, Coulter).  Transcytosis was expressed as percentage of control.   
Neutralization Assays 
Neutralization assays were performed by the lab of Nobuyuki Matoba at 
the Owensboro Cancer Research Center in Owensboro, KY as previously 
described (Montefiori, 2009; Matoba et al., 2010).  Env-pseudotyped viruses 
were prepared by co-transfection of 293T/17 cells with various env-expressing 
plasmids and an env-deficient HIV-1 backbone vector (pSG3ΔEnv) and were 
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titrated in TZM-bl cells to determine the 50% tissue culture infective dose 
(TCID50) (Figure 25). Antiviral activity was expressed as an IC50 value, which is 
the sample concentration giving 50% of relative luminescence units (RLUs) 
compared with those of virus control after subtraction of background RLUs.  The 
broadly neutralizing mAbs b12, 2G12, 2F5 and 4E10, as well as soluble CD4 
were used as positive controls. Two-hundred TCID50 of pseudoviruses were used 
for the neutralization assay. Samples and the virus were mixed and incubated for 
1 h at 37°C, to which 104 cells/well of TZM-bl cells were added and incubated for 
72 h. Luciferase activity was measured using the Britelite Plus Reagent 
(PerkinElmer, Waltham, MA). 
 
RESULTS 
Serum Antibody Titers Against p24 
 No serum antibody titers against p24 were elicited in any of the mucosally 
primed mice prior to boosting immunizations (Figure 29), although mice primed 
systemically displayed anti-p24 titers consistent with the first immunization trial 
(Chapter 4) with 6/8 mice responding to Gag by Week 3 of the trial.  After 
boosting, mice in all groups boosted with VLPs responded to the Gag protein, 
with all but two mice (one in the group primed mucosally with VLPs and one in 
the group primed with CTB-MPR) in these groups expressing antibodies against 
p24 (Figure 30).  Titers in Groups 1 and 6 were extremely significantly greater (p 
< 0.001) than mice naïve to Gag protein (Group 5), as well as very significantly (p 
< 0.01) greater than those in Group 3.   
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Serum Antibody Titers Against MPER 
 Similar to the anti-p24 priming response, no serum antibody titers against 
MPR were elicited in any of the mucosally primed mice prior to boosting 
immunizations (Figure 29).  In accordance with the systemic trial, no significant 
antibody titers against MPR were raised in the systemically primed mice prior to 
boosting, either.  Only one mouse, from Group 5 (mucosally primed with CTB-
MPR and systemically boosted with the same) responded to MPER after the first 
boost.  After the second boost, 6/8 mice in Group 1, 5/8 mice in Group 2, 3/8 
mice in Group 3, 4/8 mice in Group 4, 8/8 mice in Group 5, and 8/8 mice in 
Group 6 were responding to MPER (Figure 30).  Titers between Groups 1, 2, 3, 
4, and 6 were all statistically similar, though antibody titers in Group 5 were 
significantly (p < 0.05) higher than the rest of the groups. 
Fecal Antibody Titers Against p24   
 Anti-Gag fecal IgAs were detectible after the second boost.   Two weeks 
after the second boost, 2/8 mice in Group 1, 2/8 mice in Group 2, 3/8 mice in 
Group 3, 1/8 mice in Group 4, 0/8 mice in Group 5, and 6/8 mice in Group 6 were 
responding to p24.  Only the mice in Group 6 (primed and boosted systemically 
with VLPs) elicited significant (p < 0.01) anti-p24 titers compared to mice naïve to 
Gag.   
Fecal Antibody Titers Against MPER 
 Similar to antibody titers against p24, no fecal antibody titers against 
MPER were elicited in any of the mice prior to boosting immunizations.  Only   
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Figure 29. IgG and IgA response across all weeks of mucosal immunization.  
Serum, fecal, and vaginal secretion samples were taken on weeks 0,1, 3, 5, 7, 8, 
10, and 12.  Time points are averages of all mice in each group.  
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Figure 30. Post-boosting (Week 10) antibody titers against Gag or MPR in serum 
(IgG), fecal (IgA), and vaginal (IgA) samples.  OD values are arithmetic means of 
all mice in each group +/- S.E.M. 
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after the second boost were fecal antibody titers seen in any of the groups.  Two 
weeks after the second boost, 1/8 mice in Group 1, 3/8 mice in Group 2, 4/8 mice 
in Group 3, 2/8 mice in Group 4, 2/8 mice in Group 5, and 0/8 mice in Group 6 
were responding to MPER.  Although only two mice responded to MPER in 
Group 5, one mouse responded very strongly (OD490 = 0.74), though this high 
titer was not enough to make the average values significant over the other 
groups. 
Vaginal Antibody Titers Against p24 
 No vaginal antibody titers against p24 were elicited in any of the mice 
prior to boosting immunizations, and only three mice (one from Group 2 and two 
from Group 6) responded two weeks after the second boost. 
Vaginal Antibody Titers Against MPER 
 Unlike vaginal titers against p24, one mouse in Group 5 showed antibody 
titers against MPR in vaginal secretions at Week 7 prior to the boosts, and two 
mice in Group 5 were positive for anti-MPR antibodies at Week 8 after the 
second boost.  Two weeks after the second boost, 5/8 mice in Group 1, 1/8 mice 
in Group 2, 0/8 mice in Group 3, 3/8 mice in Group 4, 3/8 mice in Group 5, and 
0/8 mice in Group 6 were responding to MPER. 
IFN-γ ELISPOT Assay 
 Cellular responses against the Gag protein were assayed by IFN-γ 
ELISPOT (Figure 31).  The mice in Groups 1, 2, 4, and 6 responded to both Gag 
CD8+ and CD4+ peptides, while the mice in Group 5 had marginal response to 
the Gag CD4+ peptide.  Mice in Group 5 did not respond to either peptide.  
Responses seemed to be generally higher against the GagCD8+ epitope, with 
Groups 2 and 6 showing the greatest response for either peptide. 
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Figure 31. IFN-γ ELISPOT assay.  Splenocytes were harvested, isolated, and 
pooled from mice in each group and incubated with or without peptides 
corresponding to the Gag CD8+ or GagCD4+ epitopes.  Data are averages of 
triplicate values, with number of background spots from wells containing no 
peptide subtracted from this average. 
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Neutralization Assays 
 Mouse serum from the best responders was sent to collaborators for 
neutralization assays and I am currently awaiting results of these assays.   
Transcytosis Assays 
 Mouse serum from each of the mice in the trial was sent to collaborators 
for performing transcytosis assays and I am currently awaiting results of these 
assays.   
 
DISCUSSION 
 After a successful trial that resulted from VLPs used to prime and boost 
mice systemically, a mucosal trial utilizing a prime-boost strategy was employed 
to test the effectiveness of intranasal priming with systemic boosting of plant-
produced VLPs, CTB-MPR, or a combination of both.   
  The mucosal priming of all groups: either with VLPs (with either 
murabutide or CT as adjuvants) or CTB-MPR was not able to elicit significant 
antibody titers in serum, fecal, or vaginal samples before boosting.  Although this 
lack of mucosal priming response was discouraging, the results were fairly 
consistent with previous studies employing the mucosal priming with CTB-MPR, 
in which only marginal (or no) response was seen prior to boosting 
immunizations (Matoba et al., 2004; Matoba et al., 2006).  In accord with the 
previous systemic trial, i.p. priming of VLPs (Group 6) was able to elicit significant 
serum titers of antibodies against Gag, although the lack of response against 
MPER in these mice prior to boosting was also confirmed in this trial. 
 Despite the lack of response during mucosal priming immunizations, 
systemic boosting was able to elicit significant antibody titers against Gag and 
  107 
gp41 in serum, fecal, and vaginal samples in many of the groups.  Systemic 
boosting with VLPs was able to elicit anti-p24 antibodies in all but two mice 
boosted with the VLPs.  Although there was no significant difference in anti-p24 
antibodies post-boost between the groups boosted with VLPs, only Groups 1 and 
6 (primed systemically with VLPs or primed mucosally with the use of murabutide 
adjuvant, respectively) were able to elicit significant titers over mice naïve to the 
Gag protein.  Once again, this confirms the effectiveness of VLP systemic 
priming and boosting to elicit a response against Gag, but it also suggests the 
effectiveness of mucosal priming with systemic boost to elicit this same 
response.  Mucosal response against Gag was limited in all groups either primed 
or boosted with VLPs, although 6/8 mice were positive for IgAs in fecal samples 
in Group 6, with these levels being significant against those in Groups 4 and 5.  
Responses from Groups 1, 2, and 3 (mucosally primed with VLPs) were all 
statistically similar, and though their responses were not statistically different 
from Groups 4 and 5 (primed with CTB-MPR), antibody responses and number 
of responders were all greater in the VLP primed groups compared to those 
primed with CTB-MPR.  While this evidence is not statistically significant, it does 
suggest that priming with VLPs might assist in eliciting a mucosal response 
against Gag, though this response is not as great as that elicited with systemic 
priming with VLPs.  Unfortunately, very little response against Gag was 
discovered in vaginal secretions of mice in any group.  Only three mice 
responded two weeks after the last boost (one in Group 2 and two in Group 3).   
 Serum antibodies against MPER were not seen until after boosting. 
Although one mouse from Group 5 responded after only one boost, the majority 
of serum anti-MPER antibody response did not occur until two weeks post-boost 
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in all groups.  Systemic boosting with CTB-MPR following mucosal priming with 
the same (Group 5) elicited extremely significant (p < 0.001) levels of antibodies 
as compared to naïve mice, consistent with previous studies (Matoba et al., 
2006).  Unfortunately, mucosal priming with VLPs and boosted with either VLPs 
or CTB-MPR (Groups 1, 2, and 3) elicited only marginal levels of antibodies, and 
the same was true for mucosal priming with CTB-MPR and boosting with VLPs.  
Although 8/8 mice responded in Group 6 (systemically primed and boosted with 
VLPs), the levels of antibodies was lower in this group than in the CTB-MPR 
primed and boosted group (Group 5).  However, it should be noted that these two 
groups were not statistically significantly different.  Only low levels of antibodies 
and a total of 12/48 mice responded to MPER in fecal samples.  The two 
responders in Group 5 had two of the highest responses, but no group reached 
statistically significant responses in comparison to naïve mice.  Mice in Groups 2, 
3, and 4 had similar responses, but only one mouse in Group 1 and zero mice in 
Group 6 responded to MPER in fecal samples.  The results of MPER response in 
fecal samples is inconclusive, but it is suggested that mice mucosally primed with 
CTB-MPR and boosted systemically with the same can elicit a moderate IgA 
response in fecal samples, while systemic priming and boosting with VLPs was 
largely ineffective in eliciting an anti-MPR response in mice.  In consistence with 
low levels of anti-MPER antibodies in fecal samples, only 12/48 mice from all 
groups responded to MPER in vaginal secretions, with no statistical significance.  
Once again, two mice in Group 5 (the same mice with higher anti-MPER 
response in fecal samples) had two of the highest overall responses, while 
vaginal anti-MPER responses from other groups were fairly insignificant.  
Consistent with anti-MPER fecal results, no anti-MPER antibodies were detected 
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in vaginal secretions from mice in Group 6.  Overall, the results of anti-MPER 
response in vaginal secretions are congruent with results of anti-MPER response 
in fecal samples.  All of these results suggest that while systemic priming and 
boosting with VLPs can be successful in eliciting antibody responses against 
Gag and gp41, mucosal priming may not be nearly as effective in this case.   
 In addition to the humoral and mucosal immue responses, the cellular 
responses against peptides corresponding to Gag CD4+ and CD8+ epitopes 
were also explored.  Mice primed (either mucosally or systemically) and boosted 
with Gag/dgp41 VLPs had responses to both peptides, suggesting a cellular 
response against Gag in these groups.  Mice primed and boosted systemically 
had higher responses than the mucosally primed groups.  Mice receiving either 
only a priming immunization or a boosting immunization with the VLPs had lower 
responses than those groups that were both primed and boosted with the VLPs.  
Mice primed and boosted with CTB-MPR did not respond to either peptide.   
These results suggest that both CD8 and CD4 T-cell responses against Gag 
were elicited with the VLPs. 
 At the current time, results of functional assays assessing the quality of 
antibodies produced in this trial are not available, as terminal samples from mice 
were collected just prior to publication.  As with the systemic trial, it is my hope 
that the modest levels of antibodies elicited by the mucosal trial are able to block 
transcytosis of and neutralize HIV-1 virus, and thus be consistent with previous 
studies using Gag/Env VLPs and MPER. 
 Overall, the results of this trial show that although antibodies against Gag 
or gp41 were not elicited during mucosal priming immunizations, plant-produced 
VLPs can elicit antibodies against both Gag and gp41 proteins in serum and 
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fecal samples after a systemic boost, offering further evidence that plant-based 
Gag/dgp41 VLPs could provide an effective component for future HIV-1 
immunization trials.   
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Chapter 6 
SUMMARY AND OUTLOOK 
HIV/AIDS is one of the largest global epidemics with more than 33 million 
people currently infected worldwide and more than two million new infections 
occurring yearly (UNAIDS/WHO, 2009).  Despite over two decades of research, 
an effective prophylactic vaccine against HIV remains elusive (Johnston and 
Fauci, 2008), but recent clinical trials have given researchers hope and direction 
in which to focus their efforts (Benmira et al., 2010). 
Some of the recent successes both in clinical and animal trials have 
focused on utilizing mucosally-targeted, highly conserved HIV-1 antigens as 
vaccine candidates.  Combating the challenges of the hypervariablity of HIV-1 
and the high rates of mucosal transmission of the virus, these candidates provide 
hope in overcoming some of the substantial hurdles experienced by previous 
failed trials.  In addition to these challenges, if a vaccine is to be effective in 
reaching the majority of the at-risk population, largely located in developing 
countries, it must be inexpensively manufactured, stored, and distributed.  A 
vaccine candidate that addresses all of these components could be successful in 
accomplishing a decline in the rates of new infection worldwide, eventually 
leading to the eradication of the epidemic. 
To this end, a vaccine candidate based on a Clade C Gag VLP with 
deconstructed gp41 (dgp41) proteins embedded in its membrane envelope was 
developed and expressed in N. benthamiana.  By utilizing highly conserved, 
mucosally-targeted epitopes within gp41 in combination with clade-specific, CTL-
inducing Gag VLPs as a platform with which to introduce the non-immunogenic 
gp41, I hoped to induce both mucosal and humoral responses against both 
  112 
proteins.  By expressing these VLPs in Nicotiana benthamina, I hoped to 
overcome the cost and scale limitations of other cell culture systems, which will 
prove beneficial for distributing the successful vaccine candidate to the at-risk 
populations around the globe. 
 The expression of HIV-1 Gag and envelope proteins in plants has not 
been studied extensively to date.  Results from expression studies in plants with 
these proteins have varied tremendously, but only a few researchers 
experienced success with moderate levels of expression.  Not only was I able to 
express p55 Gag and gp41 in transient expression systems, I was able to create 
stably transgenic plants expressing moderate levels of Gag.  In addition to 
expressing both of these proteins separately, I was also successful in co-
expressing the two proteins, which seemed to stabilize the expression of both 
Gag and dgp41.   
 Although simply expressing these two proteins together was a first in 
plants, I wanted to ensure that the Gag protein was successfully forming VLPs 
which incorporated the dgp41 into the envelope.  One other group (Scotti et al., 
2009) was able to express full length p55 Gag in plants that developed into 
VLPs, but these particles were not fully characterized and it was not determined 
if these particles were enveloped or not. 
 This study was the first to fully characterize enveloped VLPs in N. 
benthamiana.  The results of the sucrose density sedimentation, Optiprep density 
sedimentation, trypsin digestion assay, and TEM all suggested that Gag is 
forming ~100 nm VLPs in N. benthamiana.  In addition to expressing Gag in 
plants, I was able to co-express dgp41 with the Gag VLPs.  In addition to co-
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expressing the two proteins, all of my biochemical assays have suggested that 
the two proteins are assembling together into enveloped VLPs.   
 The expression and accumulation of HIV-1 Gag/dgp41 VLPs within plants 
presents a milestone in the field of plant biology, but the end goal of the project 
was to determine if these particles were immunogenic.  The immunogenicity of 
HIV-1 Gag/Env VLPs (produced in other cell culture systems) has been 
established in a number of animal trials in the past, but the immunogenicity of 
plant-expressed HIV VLPs (with or without surface-displayed Env proteins) had 
not been tested until this study.   
 During the first trial, I demonstrated that plant-based VLPs can elicit 
immune responses against both Gag and dgp41 when used as the antigen in 
either priming or boosting injections in either homologous or heterologous 
antigen platform prime-boosts in conjunction with CTB-MPR.  Highly significant 
levels of antibodies were raised against the MPER region of gp41 after boosting 
with VLPs, and these levels continued to rise throughout the course of the study, 
suggesting that the antibodies are robust and long-lived.   Levels of antibodies 
after boosting suggested that VLPs can be as effective as CTB-MPR in eliciting 
an anti-MPER response. 
 In addition to the elicitation of anti-MPER antibodies, extremely significant 
titers of antibodies specific to the Gag protein were also elicited in groups that 
were either primed or boosted with the VLPs, with a 100% response rate in mice 
primed with the VLPs.  Similar to anti-MPER titers, anti-Gag antibody titers 
remained high throughout the remainder of the study even when mice were 
boosted with a construct that did not contain Gag.  It was also determined that 
mice which only received two boosters with VLPs (primed with CTB-MPR) were 
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still able to elicit significant levels of anti-Gag antibodies.  All of these results 
were promising, and inspired the use of these particles in additional immunization 
experiments with varied routes of immunization. 
 A mucosal trial utilizing a prime-boost strategy was employed to test the 
effectiveness of intranasal priming with systemic boosting of plant-produced 
VLPs, CTB-MPR, or a combination of both.  In congruence with previous studies 
(Matoba et al., 2004; Matoba et al., 2006), mucosal priming with CTB-MPR did 
not elicit significant titers of anti-MPER antibodies prior to boosting 
immunizations, and mucosal priming with VLPs mimicked this response.   
Promisingly, in accord with the previous systemic trial, i.p. priming of VLPs 
(Group 6) was able to elicit significant serum titers of antibodies against Gag, 
although the lack of response against MPER in these mice prior to boosting was 
also confirmed in this trial. 
 Systemic boosting following mucosal priming was able to elicit significant 
antibody titers against Gag and gp41 in serum, fecal, and vaginal samples in 
many of the groups.  Although there was no significant difference in anti-p24 
antibodies post-boost between the groups boosted with VLPs, only mice primed 
systemically with VLPs or primed mucosally with the use of murabutide adjuvant 
were able to elicit significant serum titers over mice naïve to the Gag protein.  
Once again, this confirms the effectiveness of VLP systemic priming and 
boosting to elicit a response against Gag, but it also suggests the effectiveness 
of mucosal priming with systemic boost to elicit this same response.  Mucosal 
response against Gag was limited in all groups either primed or boosted with 
VLPs, although significant levels of fecal IgAs were elicited in mice systemically 
primed and boosted with VLPs, suggesting that mucosal priming with VLPs might 
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assist in eliciting a mucosal response against Gag.  Unfortunately, very little 
response against Gag was discovered in vaginal secretions of mice in any group, 
but the little response that was elicited was manifested in groups mucosally 
primed with VLPs. 
 Systemic boosting with CTB-MPR following mucosal priming with the 
same elicited extremely significant (p < 0.001) levels of antibodies against MPER 
as compared to naïve mice, which was consistent with previous studies (Matoba 
et al., 2006).  Unfortunately, mucosal priming with VLPs and boosted with either 
VLPs or CTB-MPR elicited only marginal levels of antibodies, and the same was 
true for mucosal priming with CTB-MPR and boosting with VLPs.  A 100% 
response rate for anti-MPER serum antibodies was seen in mice systemically 
primed and boosted with VLPs, though the ODs of this group were lower than 
those in the CTB-MPR primed and boosted group.  The results of MPER 
response in fecal samples are inconclusive, but it is suggested that mice 
mucosally primed with CTB-MPR and boosted systemically with the same can 
elicit a moderate IgA response in fecal samples, while systemic priming and 
boosting with VLPs was largely ineffective in eliciting an anti-MPR response in 
mice.  In consistence with low levels of anti-MPR antibodies in fecal samples, 
only 12/48 mice from all groups responded to MPR in vaginal secretions, with no 
statistical significance.  Overall, the results of anti-MPR response in vaginal 
secretions are congruent with results of anti-MPR response in fecal samples.  All 
of these results suggest that while systemic priming and boosting with VLPs can 
be successful in eliciting antibody responses against Gag and gp41, mucosal 
priming may not be nearly as effective in this case.   
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 At the current time, results of functional assays assessing the quality of 
antibodies produced in this trial are not available, as terminal samples from mice 
were collected just prior to publication.  As with the systemic trial, it is my hope 
that the modest levels of antibodies elicited by the mucosal trial are able to block 
transcytosis of and neutralize HIV-1 virus, and thus be consistent with previous 
studies using Gag/Env VLPs and MPER. 
 Overall, the results of this trial show that although antibodies against Gag 
or gp41 were not elicited during mucosal priming immunizations, plant-produced 
VLPs can elicit antibodies against both Gag and gp41 proteins in serum and 
fecal samples after a systemic boost.   
 The promising results from both the systemic and heterologous prime-
boost immunization trial suggest that plant-based Gag/dgp41 VLPs suggest that 
the VLPs might make an attractive candidate for an ant-HIV-1 vaccine.  
Additional animal studies utilizing different antigen levels, adjuvants, routes of 
inoculation, and other protein platforms can be performed to explore the best 
immunization protocol for eliciting strong mucosal and systemic immune 
responses.  Successful protocols can then be used in additional animal models, 
such as rabbits and eventually non-human primates.  Success in these animal 
models could lead to the use of the plant-produced VLPs in human clinical trials. 
 In addition to exploring other protein partners with which to immunize, the 
partnering of antigen vaccines with DNA vector vaccines is also an angle in 
which to explore.  The moderately effective RV 144 trial utilized a recombinant 
canarypox DNA vector priming immunization regimen with  gp120 boosts (Rerks-
Ngarm et al., 2009).  In addition to the success of this clinical trial, the use of 
DNA vector priming immunizations coupled with VLP-based boosting 
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immunizations have been successful in eliciting Th responses and neutralizing 
antibody responses in non-human primates (Radaelli et al., 2003; Zanotto et al., 
2003).  This method of immunization might hold promise with the use of plant-
based Gag/dgp41 VLPs.  By priming with a DNA vector vaccine such as a pox-
vector based vaccine (Pantaleo et al., 2010) and boosting with the plant-
produced Gag/dgp41 VLPs, I might see an even greater immune response than 
that of either candidate alone. 
 All of these options will be explored in the future in hopes of one day 
formulating a successful vaccine regimen against HIV-1 and halting the spread of 
the devastating epidemic. 
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